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ABSTRACT
Flannery, Tiffany L. M.S. Department of Biological Sciences, Wright State University,
2017. Enhanced Neurogenesis in Subventricular Zone of Rats That Voluntarily Ingest
Fluoxetine and Simvastatin Combination Treatment.

Stroke is one of the leading causes of deaths as the risk factors, both controllable and
uncontrollable, are many. We first concentrated on a stress-free way to deliver the drugs.
Our preference was to have the animals ingest the drugs, which led us to a reliable
method for orally administering medication to the animal models. Using three different
drug combinations, we tested the effects on neurogenesis without stroke. We found the
drug combination of Fluoxetine/Statin/Ascorbic acid increases neurogenesis 19 fold
when compared with control. Lastly, we looked at the gene changes in the cortex of the
animal models that had been administered our drug treatment. We noted that the
fluoxetine treatment group was involved in up-regulated genes showing genetic themes
related to molecular functions for channel activity and that the fluoxetine/statin
combination treatment group was associated with clotting activity as well as an immune
response.
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Introduction
Stroke is one of the leading causes of deaths worldwide and although functional
loss depends on the type of stroke and location, severe strokes can be fatal [1]. In the
United States alone, 700,000 strokes occur every year [2]. The three different kinds of
stroke are ischemic, hemorrhagic and transient ischemic attack (TIA) [3]. The loss of
blood flow to an area of tissue constitutes ischemic stroke, while the leaking of blood into
tissue defines hemorrhagic stroke. Ischemic stroke is caused by a thrombus or an
embolus. A thrombus forms in a blood vessel or the heart but does not travel to any other
part of the body, while an embolus travels to an alternate part of the body. Both are blood
clots that can adhere to the sides of a vessel and cut off blood supply and oxygen to
surrounding tissues. Hemorrhagic stroke occurs when a vessel inside the brain bursts and
leaks blood into the adjacent tissues [3]. TIAs are sometimes called ‘mini strokes’ and
often precede a stroke. Forty percent of people who suffer a TIA will also suffer a stroke
in the future [3].
Roughly 1 in 19 deaths in the United States are attributed to stroke [4]. Some of
the more obvious risks include controllable factors such as, high blood pressure, tobacco
use, diabetes mellitus, high cholesterol, a sedentary lifestyle and obesity. According to
the National Stroke Association, stroke can occur at any age but is more common in older
people, with this risk doubling every 10 years, starting at the age of 55, making [3]
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age, an uncontrollable factor, one of the biggest risks. Other uncontrollable factors are
gender, heredity and race, as well as a prior stroke. Having a prior stroke, even a TIA,
exacerbates risk of future stroke [5]. For our purposes, we will focus on the treatments
and risks of ischemic stroke.
Treatment for ischemic stroke can range from thrombolytics and aspirin (an antiplatelet) administered acutely to retrieval devices. Thrombolytics, like the tPA (tissue
plasminogen activator) alteplase, can only be helpful when administered quickly within a
small window of time. They work by breaking down the clots so that the hypoxic tissue
can reperfuse [3]. The limited amount of time between stroke onset and the necessary
administration of tPA highlights the importance of recognizing the signs of stroke as
quickly as possible. Figure 1 shows the mechanism of action of thrombolytic drugs.
Tissue plasminogen activator does not come without risks. One in fifteen people may
develop hemorrhaging and 1 in 30 can be harmed more than helped by the treatment [2].

Figure 1 Mechanism of action of thrombolytic drugs.
Step 1: tPA binds to fibrin on the surface of the clot. Step 2: This activates fibrin-bound plasminogen.
Step 3: Plasmin is cleaved from the plasminogen associated with the fibrin. Step 4: Fibrin molecules
are broken apart by the plasmin and the clot dissolves. Source: Klabunde, Richard E.
Cardiovascular Pharmacology, Thrombolytic (Fibrinolytic) Drugs 2007;
http://www.cvpharmacology.com/thrombolytic/thrombolytic.
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Aspirin is an NSAID (non-steroidal anti-inflammatory drug) that also acts as an
antiplatelet. As an anti-platelet, it decreases the production of prostaglandins, which
ultimately decreases the production of Thromboxane A2 (TXA2) further down the
cascade. Salicylic acid, an active metabolite in aspirin, has been used for centuries to treat
ailments such as fever, pain and inflammation [6]. In Figure 2, the mechanism of action
for aspirin is shown by the inhibition of cyclooxyegenase-1 (COX-1). The key ingredient
in aspirin is acetylsalicylic acid, which adds an acetyl group to COX-1, through an
irreversible reaction and will inhibit the synthesis of prostaglandins [7]. Recent studies
have shown that aspirin also plays a role in eNOS (endothelial Nitric Oxide Synthase)
recovery and sustainability [8].

Figure 2 The mechanism of action for aspirin is shown by the inhibition of cyclooxyegenase-1.
Aspirin inhibition of COX-1 decreases TXA2 production. Source: Gasparyan, A. Y. et al. J Am Coll
Cardiol 2008;51:1829-1843

If the clot is in a position to be retrieved, there are a couple of devices, which
could be used, and each comes with its own challenges. The MERCI retriever
(Mechanical Embolus Removal in Cerebral Ischemia) was the first to be approved by the
3

FDA [9]. The MERCI retriever has a corkscrew on the end of guide and uses suction to
dislodge and remove the occlusion. A challenge to using the device is the need to get
distal to the embolus for effectiveness [10]. The Penumbra clot retrieval system has a
vacuum located at the tip of the device and does not require distal deployment. Instead,
the device is guided to a position that is proximal to the clot and is then aspirated until
completely removed [11]. A third retriever, Solitaire Flow Restoration Revascularization
Device, claims to restore flow, retrieve the clot and revive the tissue [12]. In trials, the
Solitaire device outperformed the MERCI with overall better clinical outcomes and
safety [13].
Even with the success of devices, the standard in care remains intravenous tPA
within the 4.5-hour window following stroke onset. It has proven difficult to predict a
patient’s success with retrieval devices and decisions are made on an individual basis
[14]. Most studies conclude that energy should be focused on shortening the time
between onset and treatment. While the standard window for tPA treatment is around 4.5
hours, the timeframe for device retrieval is about 8 hours from onset [10].
The American Heart Association has been working to reduce the incidence of
acute ischemic stroke and the injuries caused by this event. The approach includes public
education as well as strict guidelines and shared protocols for health professionals at
every level. The most important detail in both public and professional education has been
stroke sign identification and immediate action. Less than 50% of 9-1-1 calls related to
stroke victims were made within the first hour of onset and less than half of those callers
knew that the symptoms they were reporting were indicative of stroke [15].
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Public education about the warning signs of stroke has used a couple of
approaches. One campaign urged remembering the “5 suddens”. There are five early
stroke warning signs including sudden weakness, sudden speech difficulty, sudden visual
loss, sudden dizziness and sudden severe headache [16]. More recently, the message has
moved back to FAST. FAST refers to facial droop, Arm weakness, Speech difficulty and
Time to call 9-1-1 [17]. Although not all of the symptoms of stroke are included in the
FAST acronym, one study claimed that 88.9% of the ischemic strokes and TIAs were
identified with one or more of these symptoms [18].
Time cannot be emphasized enough to the public and calling for emergency
transport tags the patient as a high priority. In order for stroke to be properly diagnosed, a
physical exam and imaging scans must be performed. The patient arriving by EMS
(emergency medical services) will be seen by a doctor sooner and have imaging done
faster, which in turn means the stroke will be able to be treated quicker. This is important
due to the critical window for treatment with tPA [19]. At this time, only 53% of stroke
patients use EMS [20].
Other benefits for using the EMS system include the evolving guidelines for
improving stroke care, involving the organization of both private and public resources.
The implementation strategies ensure that stroke patients will receive the quickest and
most effective care available within a certain period [21]. With time being the main
variable with respect to positive outcome, using the EMS system is of the utmost
importance because while the patient is being transported a variety of timesaving tasks
can be performed. Patient history, starting an IV, blood samples and glucose levels can
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all be accomplished in route to the emergency room. Having the hospital expecting the
patient cuts down on time between onset of stroke and actual stroke treatment [22].
With all of the emphasis put on the critical treatment window characteristic of
stroke, it is necessary to find methods we can use after this window has passed. Research
has focused effort on animal models in hopes of finding a delayed treatment for stroke
that will increase neurogenesis and recover lost functionality. For this research, we used
an aged rat animal model, with animals over a year old, to simulate the average age of
stroke in humans. Although stroke can occur at any age, almost 75% happen over the age
of 65 [23]. After trying to induce stroke by a distal electrocoagulation in the MCA and
performing immunohistochemistry to label for neurogenesis, we found no sign of infarct
and only the effects of Doublecortin labeling. We then used these animals as surgery
shams, since a stroke was not induced but the rest of the procedure matched that for
inducement of stroke. Our focus turned to stimulating and quantifying changes in
neurogenesis through various pharmacological treatments, as well as examining any gene
alterations that may take place in response to the treatment.

The Experiment
We wanted our animal model to be comparable to the human condition. Using
aged rats was the first step. Rats typically have a lifespan of roughly 2 years [24], so a
one-year-old rat is considered middle-aged, and our lab has evidence that female rats at
this age are typically post-menopausal. We had three Hypotheses and three Specific Aims
in this thesis:
Hypothesis 1. Removing stress through a voluntary feeding method will enhance
the ability of the drugs to work.
6

Specific Aim 1. Develop a drug delivery method that enables rats to orally take a
fixed dosage (mg/kg) of medicine over a period of time.
Hypothesis 2. Statins and/or Selective Serotonin Reuptake Inhibitors will act to
increase neurogenesis in the Subventricular Zone of aged rats.
Specific Aim 2. Test four treatment groups to determine if the drugs increase
neurogenesis in the Subventricular Zone of age rats. The four treatment groups will
include control (no drugs, just vehicle), Statin combo (0.5mg/kg simvastatin, 20mg/kg larginine and 20mg/kg ascorbic acid) treatment, Fluoxetine treatment (5 mg/kg fluoxetine)
and Fluoxetine combo treatment (0.5mg/kg simvastatin, 20mg/kg l-arginine and 20mg/kg
ascorbic acid, 5 mg/kg fluoxetine).
Hypothesis 3. The FDA approved drugs (statins and SSRIs) used in this study are
working through currently unknown mechanisms to increase neurogenesis.
Specific Aim 3. Look for rat Gene Chip changes in response to drug treatment in
cortical tissue.
Typically, when the brain is injured, the natural response includes injury-induced
neurogenesis, synaptogenesis and angiogenesis, to aid in the recovery as quickly as
possible [25]. During neurogenesis, neuroblasts develop from a neural stem cell
population in the subventricular zone (SVZ) of the lateral ventricles or the dentate gyrus
(DG) of the hippocampus. The subventricular zone can be found along the outer walls of
the lateral ventricles [26]. From here, the neuroblasts migrate to the Olfactory bulb via
the Rostral Migratory Stream, where they typically become interneurons [27]. Figure 3
shows the path the neuroblasts travel [27]. Injury induced angiogenesis, synaptogenesis
and neurogenesis work together as endogenous recovery mechanisms to support healing
7

of the damaged area [28]. When the neuroblasts arise and their amount of chemokine
exposure during migration, determines whether they become astrocytes,
oligodendrocytes, neurons or interneurons [29].

Figure 3 Neuroblasts path of travel.
a | In rodent brains, postnatal neuronal migration is evident in three main areas: the cerebellum
(CB), the hippocampus (Hipp) and the rostral migratory stream (RMS). A small number of neurons
also complete their migration into the hypothalamus (Hyp) at) at around the time of birth. Distinct
germinal zones (green) give rise to neurons that migrate to adjacent target zones (red). Lighter shade
indicates that migration in these regions occurs primarily during the very early postnatal period and
does not persist into adulthood. Cells born in the anterior subventricular zone (SVZ, inset) initiate
their migration from the SVZ (1) as chains (2) streaming towards the olfactory bulb (OB), where
they end their migration (3). b | A highly restricted pattern of neuronal migration is evident in the
postnatal human brain. There are pools of neural precursors (green) around the walls of the lateral
ventricles (V). Occasional, TUJ1 (beta III-tubulin)-positive, elongated neurons (red dots),
reminiscent of actively migrating ones, have been identified adjacent to these precursor pools, but
whether these represent migrating neurons is unclear. Although there is no RMS in humans, isolated
new neurons have been reported in the olfactory bulb. In the hippocampus, sub granular zone
precursors continue give rise to new neurons, which then migrate short distances to the adjacent
dentate gyrus (DG). As in rodents, human cerebellar neuronal migration is limited to the very early
postnatal period. EGL, external granule cell layer; IGL, internal granule cell layer; OE, olfactory
epithelium; SGZ, sub granular zone [27]

During ischemic stroke neuroblasts abandon the normal migratory path from the
SVZ and are guided by a cascade of molecular signals toward the ischemic tissue [30].
This process begins 3-4 days after stroke and can continue for as long as 4 months [31].
8

Time-lapsed imaging and labeling with Dil (di-alkyl indocarbocyanine dye) has shown
these new neurons have retained the ability to divide [30]. In order to influence recovery
after stroke, it becomes important to find treatments that stimulate this stem cell
population.

Simvastatin
HMG-CoA reductase inhibitor (3-hydroxy-3-methylglutaryl) is a cholesterollowering agent from a family of drugs called statins [32]. Patients being treated with
statins are shown to have a resistance to myocardial as well as cerebral infarctions
(stroke) because this prophylactic treatment augments cerebral blood flow, reduces
infarct size and improves neurological function through selective up-regulation of
endothelial NO synthase (eNOS) [32]. Scientists found that these lipid-lowering drugs
actually have many effects outside of improving cholesterol levels including enhanced
neurogenesis, synaptogenesis and angiogenesis [33]. These effects have been shown
experimentally in rats when treated after 24h (delayed) in a middle cerebral artery
occlusion (MCAO) in Dr. Michael Chopp’s laboratory [33]. In this study,
immunohistochemistry labeling included BrdU (label for neurogenesis), von Willebrand
factor (endothelial cell marker) and synaptophysin staining (marker for synaptogenesis)
and to determine neural phenotype; double immunochemistry staining was performed to
discern BrdU with the specific progenitor marker, TUJ1 (a marker for an immature
neuron) [33]. Testing for vascular endothelial growth factor was done using a VEGF
ELISA kit and as a complementary measurement of angiogenesis, a corneal angiogenesis
assay was done. The results from all tests indicated that statins induced increases in
angiogenesis, synaptogenesis and neurogenesis [33].
9

A study performed in 2011 with simvastatin (1mg/kg), induced angiogenesis in
the hippocampus of rats, which were given a brain injury or sham surgery. Again, it was
a delayed treatment with the statin starting one day after operation and continued for 2
weeks [34]. Simvastatin was found to mediate angiogenesis through the VEGFR2/PI3k/Akt/eNOS pathway. Simvastatin stimulates phosphorylation of eNOS and
activates this pathway [34]. For eNOS activation to be enhanced, eNOS must be
phosphorylated and statins stimulate the coupling of eNOS and Hsp90 (heat shock
protein), which phosphorylates the eNOS [35]. Statins may reduce the effect of stroke by
up-regulating eNOS [32].
The graph in Figure 4 shows where simvastatin was used to treat mice with
normal cholesterol levels for 14 days at 0.2, 2.0 and 20 mg/kg before MCAO. The results
illustrate that infarct volume decreased as the dose of statin increased.

Figure 4 The effects of Simvastatin on cerebral infarct.
The effects of Sim (0.2, 2.0 or 20 mg/kg s.c. daily for 14 days) on cerebral infarct volume after 2 h of
filamentous MCA occlusion and 22 h of reperfusion compared with vehicle-injected 129/SV mice.
Cerebral infarct volume was determined quantitatively by TTC staining. Smaller infarct sizes were
confirmed with an indirect method that corrects for brain swelling (n=9-18 per group).
*p<0.05;**p<0.01 (Endres et al., 1998)
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More promise was shown with statins when studies were performed with
atorvastatin. Administration of atorvastatin to rodents 1 day after stroke, led to significant
increases in vascular endothelial growth factor (VEGF), cell proliferation and
neurogenesis [33]. VEGF is an angiogenic factor and plays a role in vascular
permeability [36]. Several growth factors, including VEGF, are expressed after cerebral
ischemia. These growth factors induce endothelial cells to proliferate, triggering
angiogenesis [37]. VEGF induces the expression of endothelial nitric oxide synthase
(eNOS) [38]. To stimulate angiogenesis, eNOS produces low concentrations of nitric
oxide NO [37], which acts to dilate blood vessels, increasing blood flow.
The pleiotropic effects of statins, shown in Figure 5, have been found to reduce
inflammation, platelet aggregation [25] and regulate glutamate metabolism to decrease
excitotoxic effects, as well as contribute to the immune system via reductions in
expression of major histocompatibility complex II (MHCII) [39]. Atorvastatin, lovastatin
and simvastatin were also shown to directly affect apoptosis by decreasing the
prenylation of p21 in Rho B, a small GTPase that plays an important role in regulating
this pathway [40]. HMG-CoA reductase inhibitors induce apoptosis by reducing the
isoprenoid concentration, which then reduces protein prenylation [40]. Other studies have
found them reducing insulin-like growth factor (IGF-1) and platelet derived growth factor
(PDGF) in order to decrease apoptosis [41] [42].

11

Figure 5 Pleiotropic effects of statins on the vasculature Clinical Science (2003) 105, 251-266

Statins have been shown to improve endothelial function even without a change in
cholesterol levels, suggesting an alternate mechanism in play. At this time, stroke is
treated prophylactically with agents that block the clotting cascade, but this type of
treatment is risky as a person ages, as falls could lead to prolonged bleeding. This
treatment is limited in that it decreases incidence, but not the size of the infarct [32].
Furthermore, experiments with alternate means of lowering cholesterol (e.g. reduction at
the liver) have not had an impact on infarct size in stroke or positive outcome following
myocardial infarction [32].
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Fluoxetine
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). It works through the
CNS, acting to increase the neurotransmitter serotonin in the synaptic region. After
neurotransmitters are released into the synaptic cleft, they will attach to a serotonin
transporter on the original neuron that released it. The molecules attaching to adjacent
neurons either excite or inhibit them, while the molecules attaching to their home neuron
are taken back up into the neuron and repackaged for release. This reuptake process
removes excess neurotransmitter from the synapse as well as providing a means of
efficiently recycling neurotransmitter for the cell.
Fluoxetine was first approved by the FDA in December 1987 for the treatment of
depression and has since been used to treat a multitude of disorders including bulimia,
anxiety and obsessive-compulsive disorder (OCD) to name a few [43]. Patients suffering
from stroke and Alzheimer’s are also treated with this drug [44].
Acute stroke causes irreversible damage to an ischemic core. The area around the
core is called the ‘Penumbra” and is the target for treatment because it is the salvageable
tissue [45]. When the brain is injured, an inflammation response will occur stemming
from the release of pro-inflammatory cytokines from activated microglia. Microglia are
part of a healthy immune defense response in the CNS. During their resting state, they
carry out maintenance, homeostatic and surveillance roles [46]. However, when the brain
becomes injured their structure and function will change, becoming activated and they
will become phagocytic, and secrete cytokines and pro-inflammatory factors [47].
Fluoxetine has been shown to protect mesencephalic, dopaminergic and hippocampal
neurons by mediating the inflammatory properties of microglia in culture. Fluoxetine
13

suppresses the microglia inflammatory response, which inhibits the production of proinflammatory factors such as TNFα, IL-1β, NO, and ROS (reactive oxygen species) [47].
Depression is one of the most common disorders that follow stroke and will pose
limitations on recovery and rehabilitation [48]. Depression may be associated with
reduced neuronal plasticity [49]. In 2000, antidepressants were shown to have effects on
plasticity by increasing neurogenesis in the rat hippocampus [50] . The hippocampus is
the one of two sites for neurogenesis, through the lifetime, in both animals and humans
[51]. Aging has a significant effect on neurogenesis, diminishing it as we get older, and
these results were shown in rodents 8 months old [49]. Fluoxetine can induce changes in
the expression of PSA-NCAM, (polysialylated form of the neuronal cell adhesion
molecule) in middle-aged rats. When PSA-NCAM expression is increased, it is
accompanied by an increase in synaptophysin. Synaptophysin modulates plasticity and
PSA-NCAM has been shown to promote neural plasticity in rats because of its antiadhesive properties. PSA-NCAM modulates spacing between cells, regulating the
connectivity of interneurons and influencing synaptogenesis [49].
Depressed patients show a decrease in synaptophysin, which means that plasticity,
is affected. Stress shows the same effects on plasticity and neurogenesis as depression
[52] and BDNF expression is reduced in response to stress [53]. Chronic treatment with
antidepressants completely blocked the stress induced down regulation of BDNF [54],
which could cause a loss of neurons in this region. Continued depression or stress without
treatment reduces the size of the hippocampus, causing atrophy through a loss of neurons
[55]. Figure 6 shows results from a study analyzing the effects of fluoxetine on different
parts of the brain.
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Figure 6 Effect of fluoxetine treatment on different structures in the brain.
Graphs showing (A) the body weight change through the experiment for the control and fluoxetine
group and (B) the effect of the chronic fluoxetine treatment on the volume of the different structure
studied. Statistically significant (*P < 0.05, **P<0.01 ***P<0.001) Student t-test. Guirado et al. BMC
Neuroscience 2012 13:5 doi: 10.1186/1471-2202-13-5
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Since we were using simvastatin and fluoxetine for our drug treatments, we
decided to add ascorbic acid, as well. Ascorbic acid (vitamin C, an antioxidant) was
added because we thought it might enhance the overall effects of the drug combination.
Ascorbic acid improves the effects of fluoxetine by decreasing the oxidation of serotonin
[56]. This prolongs the life of the serotonin. Statins stimulate eNOS that will then
increase BDNF [57] [32]. However, eNOS can be sensitive to oxidation and ascorbic acid
has been shown to enhance activation of this enzyme [58] [59]. Figure 7 shows how
ascorbic acid can boost the production of NO by eNOS when added to the calcium
ionophore A23187 compared to the ionophore alone.
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Figure 7 The effect vitamin C treatment has on eNOS.
Treatment with vitamin C (100µM) increases agonist-stimulated synthesis of nitric oxide (NO) by
eNOS. The calcium ionophore A23187 (2µM) was used to stimulate maximal production of NO by
eNOS. The eNOS inhibitor L-NAME (300µM) inhibits the reaction, which illustrates a direct effect of
vitamin C on eNOS activity. Controls with vitamin C alone, L-NAME alone, or A23187 + L-NAME
were not statistically different from the control treatment (data not shown). NO was measured by
conversion of L-[24C]-arginine to L-[24C]-citrulline (n=3). *P <0.01; **P=0.05 compared with control
[60]

Doublecortin, DCX
Doublecortin (DCX) is a microtubule-associated protein (MAP) that is encoded
by the DCX gene. It is transiently expressed in both the CNS and PNS during embryonic
and post-natal development [61]. DCX is expressed in the immature neurons and their
precursor cells while dividing and the daughter cells continue the expression for 2-3
weeks [61]. It is considered a MAP because it colocalizes/coassembles with microtubules
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and has the ability to directly affect the polymerization of tubulin, instigating the
formation of microtubules [61].
At the ends of neuritic leading processes, there is a high concentration of DCX,
suggesting an association with plasticity, migration, axonal guidance and dendritic
sprouting [62]. Normal migration will not occur with disruption of the DCX gene [61].
During neuronal migration, the microtubules, within the growth cone mediate the
growth cone response to chemoattractants and chemorepellents [63]. Interestingly, DCX
does not bind microtubules throughout the neuron, but rather only those in the growth
cones [64]. This is surprising as there is no local microtubule-organizing center (MTOC)
in the growth cones. Experiments where tubulin was incubated with DCX showed
microtubule nucleation, however the growth rate was not affected. The C-terminal
domain of DCX stimulates the addition of tubulin dimers thereby catalyzing the growth
of microtubule. The N-terminal domain of DCX binds the polymers and helps prevent the
microtubule from disassembling [64]. When the concentration of DCX is increased,
microtubules become more stable and do not disassemble [65]. DCX binds between the
protofilaments and the stabilization comes from the increased integrity of the lateral
contacts [66]. This stabilization provides a two-fold benefit. First, it allows the
microtubules to maintain their role as tracks for motor proteins while simultaneously
providing integrity to the outreaching growth processes [65].
After migration, there is a vast decrease in DCX expression, probably regulated
by an extracellular signal [61]. This timeframe of expression between migration and final
destination has allowed the DCX protein to become the gold standard in
immunochemical labeling for neurogenesis [67].
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Endothelial Nitric Oxide Synthase, eNOS
Endothelial nitric oxide synthase (eNOS) serves as a protectant in vascular
smooth muscle [68]. ENOS is anti-thrombotic, anti-inflammatory and anti-proliferative
for smooth muscle in the blood vessels. A lack of eNOS leads to platelet aggregation,
increased smooth muscle proliferation, greater leukocyte adhesion to the endothelium and
a rise in blood pressure [68]. Up-regulation of eNOS will lead to an increase in
circulating endothelial progenitor cells (EPC) [68]. From here we will focus on ischemic
stroke and the role that eNOS plays in the condition.
While no genetic determinations have been pinpointed, eNOS has been linked in a
positive way to recovery from ischemic stroke. Links between stroke and recovery are
bridged by physical activity, statins, hypothermia, nitrite reduction and their influence on
eNOS.
During physical training, we strengthen our cardiovascular systems. Those who
exercise regularly are less likely to experience an adverse cardiovascular event [69]. In
addition, cardiovascular exercise leads to an increase in eNOS and in turn, endothelial
progenitor cells (EPC), both circulating and in bone marrow (Fig. 8). Together eNOS and
EPCs promote vascular health by boosting angiogenesis, reducing atherosclerosis and
supporting vascular repair [69].
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Role of NO in Exercise-Induced EPC Regulation

Figure 8 The role of nitric oxide in exercise-induced EPC regulation.
(A) mRNA expression in aortic segments on day 0, 1,7,14 and 28 of training. Mean ±SEM, n=8;
*P<0.05. Effect of 28 days of exercise on EPCs in peripheral blood (B), bone marrow (C) and
spleen [70]
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The enzyme eNOS is critical under ischemic conditions. It is necessary for
arteriogenesis and angiogenesis to compensate for the loss of blood in tissues. Mice
lacking eNOS will not recover from stroke sufficiently and will continue to exhibit
deficits. In addition, statins will not assist in the angiogenesis of mice lacking in eNOS
[71]. Local delivery of an adenovirus containing an active form of eNOS assists in
improving both functional and structural deficits incurred from stroke [71].
When ischemia occurs, the endothelium of blood vessels becomes injured. Once
reperfusion begins, a cascade of events, including the release of cytokines and free
radicals, further contribute to the damage [72]. Reperfusion injury is a common
occurrence. During reperfusion, there is inflammation and endothelial dysfunction,
allowing for increased blood brain barrier permeability. The up-regulation of nitric oxide
(NO) can help mediate and at times eliminate these effects, but it depends on the amount
of NO and the source [72]. When a moderate concentration of NO is released by eNOS,
endothelial function will be preserved and inflammation will become inhibited. However,
if an increased concentration of NO is produced by inducible NOS, found in activated
inflammatory microglia, reperfusion injury will be augmented. Large amounts of NO
from inducible NOS cause the formation of the free radical peroxynitrite, which is toxic
[72]. Hypothermia will impede inducible NOS transcription, allowing for less free radical
injury [72]
This NO system can be managed through hypothermia. Lower temperatures have
a protective effect against reperfusion injury, by preserving the endothelial barrier
function and calming the inflammation response [72]. The protective effects of
hypothermia are eNOS dependent and linked to the up-regulation, expression and
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phosphorylation of eNOS. The up-regulation of eNOS after ischemia may be an intrinsic
mechanism set off by the low temperature to protect the surrounding tissues [72].
Researchers used eNOS knockout and wild-type mice for a left pulmonary hilum
occlusion surgery. The occlusion lasted for one hour, followed by five hours for
reperfusion. During the ischemic event, the left pleural cavity was kept at one of two test
temperatures: 36C (normal) or 32C (hypothermic). Hypothermia triggered an upregulation of eNOS within 5 hours of the ischemic event and an increase in eNOS
expression within 2 hours of reperfusion [72]. Several mechanisms may account for the
protective responses observed with induced hypothermia [72]. During a period of
lowered temperature, cell injury is delayed by the decreasing rate of metabolism. Since
metabolism is slowed, the cell utilizes very little ATP and lastly ion homeostasis within
the cell becomes essential [72]. Inducing brain hypothermia, using a “Cool-Cap” is a
standard treatment for neonatal hypoxia-ischemia (stroke), which can occur during a
difficult birth. At birth, the skull is thin enough to permit temperatures changes with the
cool cap, allowing increased functional recovery in neonates.
During times of oxygen deprivation, eNOS will assist in reducing nitrite to nitric
oxide. This beneficial property of nitrite is improved in hypoxic environments. Using
eNOS knockout (KO) mice showed that the reduction of nitrite is mediated by the
protein, eNOS [73]. Researchers used KO and wild-type mice for the
ischemic/reperfusion experiment. They applied sodium nitrite topically after 30 minutes
of ischemia, and allowed reperfusion for 24 hours. The deficits were reduced in wild-type
mice; however, in KO mice the deficits were increased. Chemiluminescence
demonstrated quick distribution of the nitrite within one minute of application [73].
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Since eNOS is a vasoprotective enzyme, the expression of eNOS poses many
consequences for vascular homeostasis. Because eNOS is a vasodilator, rats without the
eNOS gene are hypertensive [74]. If eNOS is inhibited in the brain, embolic processes
increase vascular resistance. The result is the brain parenchyma becomes more vulnerable
to injury via ischemia [75]. Mice lacking neural nitric oxide synthase (nNOS) are able to
resist cerebral ischemia, but this resistance can be turned off by inhibiting eNOS [75].
It would be helpful for future treatment if there were a way to artificially express
eNOS. A study was performed where a recombinant eNOS gene was administered
perivascularly to adult mongrel dogs of both sexes via CSF so that the cerebral blood
flow was not disturbed [76]. Administration was performed in vivo and dispensed to the
adventitia of the cerebral arteries. The eNOS protein was found in the invaginations of
the plasma membranes. The ventral surface of the brain revealed a higher expression of
eNOS than the dorsal surface, which was beneficial because the major cerebral arteries
are located ventrally [76]. The results were exciting because of the manner of
administration and the functional expression of the gene [76].

Drug Delivery Method
Adult neurogenesis is inhibited by stress and depression [60]. These effects have
been shown experimentally, with not only structural and functional changes in neurons,
but also alterations in both glucose metabolism and cerebral blood flow [60]. It is common
practice to utilize intraperitoneal injections (IP) as part of standard protocol due to the ease
of administration and lack of problems with appropriate dosing. Although the physiological
response depends on the methods, frequency and duration, indications of stress have been
found in such trivial situations as weighing, handling and cage cleaning for
23

individually

housed rodents [77]. The consequences manifested as tachycardia and hyperthermia. In
addition, a type of depressive state was also realized by researchers in 1997 when after
repeated saline injections the rats became subdued and remained immobile for long periods
of time [78]. If IP injections skew the overall results, it would behoove us to find methods
that are more neutral.
When testing post-stroke medications that might enhance neurogenesis, then, it
becomes important that we deliver the medication in a manner that reduces stress. After
trying a variety of substances, we found that sugar cookie dough had the best consistency
for mixing in the medications and the animals were willing and able to consume the
entire dough ball. Consuming the vehicle in its entirety was important for standardization
of the medication doses. There was no stress associated with this method, as the animals
looked forward to the feeding each day and usually consumed the dough ball with
medicine within 5 minutes.
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MATERIALS AND METHODS
Subjects
For experiments both Wistar and Fisher retired breeder rats were utilized. The
Wistar rats were male, weighing 500-750 grams (Charles River). The Fisher rats were all
females with the exception of three males, which were part of the control group. The Fisher
rats weighed 200-300 grams (Harlan). All rats were at least one year old, making this an
aged animal model, as the normal life expectancy for rats is around 2 years [24]. The Fisher
rats were used for the oral administration of medication study as well as the gene analysis
and the Wistar rats were used for the oral administration of medication study and the
neurogenesis study. Each rat had its own cage before and after surgery and the animal
protocols were approved by the Wright State University LACUC (Laboratory Animal Care
and Use Committee).

Experiment
The subjects were divided into groups that received either a distal middle cerebral
artery electrocoagulation or a sham surgery. Then these rats were divided into groups that
were either: control (no treatment), statin treatment, fluoxetine, or fluoxetine and statin
combination treatment. The rats were further divided into 2 groups of 2-week rats and 1
group of 5-week rats. (The purpose of the first group of 2-week rats (Wistar) and the 5week rats (Wistar) was to compare the differences that the treatment had on the animals
over a short period of time vs a long period). The other 2-week rats (Fishers) were sent
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for a gene analysis to look for any upregulated genes that may be associated with the
experiment.
All medication was individually weighed and placed in the middle of small cookie
dough balls in the following amounts for the Wistar strain: control-no medication, statin
combination- 0.5mg/kg simvastatin, 20mg/kg l-arginine and 20mg/kg ascorbic acid,
fluoxetine- 5mg/kg and fluoxetine and statin combination- 5mg/kg. The Fisher rats had
the same medications in the same amounts minus the 20mg/kg l-arginine in the statin
combination. The rats were fed their medication once/day beginning 1 day after the
surgery and continuing for a full two weeks or five weeks as necessary.

Voluntary Oral Administration of Drug Treatment
We used a variety of different food substances to test, which would work best as
the vehicle for our drug administration. A standard amount of the substances (4-5 grams)
were left in each rat’s cage overnight and the next day we would document which foods
were eaten in entirety. Once we had chosen our treatment vehicle, we needed a
standardized method of preparation and administration. First, we made dough balls that
were 4 grams and placed them into 60 mm glass petri dishes. A small indentation was
made in the middle of each ball and the exact amount of drugs in a fixed dosage (mg/kg)
for a specific rat (based on individual rat weight) was placed in the cavity. We then
pinched the sides together and manually mixed the drug treatment into the dough ball,
placed it back in the glass petri dish and put a plastic weighing boat on top with the rat’s
identification number. Figure 9A shows the protocol used when preparing the cookie
dough medicine balls.
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Figure 9 Cookie dough preparation and a rat consuming the cookie dough ball.
(A) Cookie dough preparation: 4 grams of dough with a cavity made in the center, drugs placed in
cavity, fold the sides, mix thoroughly and roll into a ball (B) Rat consuming cookie dough ball

It was important to use a glass petri dish because during previous feedings the rats
had chewed on or eaten part of the plastic petri dishes. In addition, each weigh boat was
labeled with a rat’s ID number and removed before placing the petri dish in the cage.
Although most rats consumed the food quickly, some ate a little slower. Knowing
this, we would leave the dough balls overnight and switch out the petri dishes the next
day, loaded with fresh cookie dough. In Figure 9B, a Fisher rat is eating the cookie dough
medicine ball roughly 3 minutes after it was presented to her in the cage.
We kept track of any uneaten cookie dough to include in our analysis of this new
approach. Any rat that left part of the medicine was documented, including all controls.
Reliability of the method was determined using the following equation, which provides a
percentage of complete ingestion of the drugs:
Reliability = 1 – (# of incidents of non-ingested drugs) / (#rats) * (# days drugs given)
The rats were given plain sugar cookie dough for 3 days in order to acclimate to
this new food item. During this 3-day trial, uneaten dough was not counted against
reliability.
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Distal Middle Cerebral Artery (MCA) Occlusion
Each rat was anesthetized using 5% isoflurane while inside an induction chamber
and after 5 minutes the anesthesia was reduced to 2.5-3%. Ointment was applied to the
eyes of the rats to prevent drying. With the Wistars, the ointment was applied before
anesthesia but it was applied afterwards with the Fishers (as they were more likely to
bite).
Once the subject was under anesthesia, it was moved from the induction chamber
to the gas mask. A Benchkote mat was placed over a heating pad that was set to 37C and
the rat was laid on its left side. The right side of the head was shaved and then cleaned
with Provoiodine, 70% isopropyl alcohol and Provoiodine, respectively.
A 2cm incision was made between the lateral canthus of the right eye and the
external auditory meatus. To decrease the pain for the animal upon awakening,
bupivivaine was applied, drop-wise along the incision. Next, the temporal muscle was
located, carefully dissected, and retracted so as not to disturb the associated
neurovascular structures. Once the zygomatic arch was exposed, the approximate location
of the MCA could be determined. In the Fisher rats, the MCA arose rostral to the fusion
of the zygomatic arch and more toward the anterior edge. However, in the Wistar rats the
MCA appeared 2-3 mm anterior to that of the Fisher rats.
A dental drill was used to make a 4-6 mm hole in the squamosal bone. A cruciate
incision was made in the Dura using a 22-gauge needle. After the MCA was identified, it
was electro-coagulated with a bipolar Malus electro-coagulator at several different
positions, both before and after it branched. Sterile bone wax was used to seal the hole
and 4-0 Vicryl sutures were used to close the surgery site. The suture line was then
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coated with Provoiodine. Animals receiving a sham surgery still had the MCA exposed,
but no electrocoagulation. Unfortunately, after the rats were euthanized, we saw no
evidence in the brain that this stroke surgery was successful in producing an infarct,
leading us to treat each animal as a sham stroke surgery and investigating
pharmacological effects on neurogenesis in the absence of stroke.

Tissue Collection and Cryosectioning
After full drug treatment of either 2 weeks or 5 weeks had been administered, the
rats were cardio-perfused. First, each rat was euthanized with an IP injection of
pentobarbital (150mg/kg) and then cardio-perfused with phosphate buffered saline (PBS)
to remove the blood. The rat was then cardio-perfused with 4% paraformaldehyde in PBS
to fix the brain tissue. Afterwards, the brains were carefully removed and cut into coronal
blocks of forebrain, midbrain, and hindbrain and stored in a 30% sucrose solution until
time for cryosection and immunohistochemistry. A small cut was made on the ventral
right side of the brain for quick orientation during microscope analysis.
Brains were sliced in coronal sections at 50-micrometer thickness using a cryostat
machine. Each block of brain was placed on a chuck prepped with Optimal Cutting
Temperature compound (OCT) and then embedded in OCT. The chuck was then placed
in a Styrofoam container and completely covered with powdered dry ice for
approximately 10 minutes. The embedded brain tissue was placed in the cryostat machine
to equilibrate to the appropriate temperature, of -26 to -28 C. This normally took about
15 minutes and was adjusted depending upon the humidity and temperature of the room
each day. Fresh razor blades were used to ensure clean cuts, less tissue damage and
minimal curling. Four scintillation vials filled with PBS were used for each cutting
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session. A session consisted of collecting 15-20 slices in each vial and continued with
four more vials until all of the tissue had been sliced. The vials were all labeled
appropriately with the number of the rodent and part of the brain it contained.

Immunohistochemistry
Immunohistochemistry was performed using free-floating sections, and the
Vector Laboratories ABC technique. Protocol was followed per the immunoperoxidase
system of Vectorlabs (Vector laboratories catalog # SP-2001). The general instructions
for the ABC method include incubation with a blocking solution containing serum of the
host of the secondary antibody, application of unlabeled primary antibody, wash and
application of the biotinylated secondary antibody, wash and application of the preformed
avidin and biotinylated horseradish peroxidase (HRP) conjugate. Lastly, following the
final wash, the DAB substrate is added, one of the most common substrates utilized with
HRP. The free radicals produced by the peroxidase, oxidize DAB and cause it to
crystallize. This oxidation product amplifies the signal at the antigen sites. To mark areas
of neurogenesis, a Doublecortin primary antibody was used with a 1:500 concentration.

ABC Protocol
Tissue sections were incubated with 1% blocking reagent solution overnight at
4C, in a standard tissue culture six well plate with 5ml solution in each well and the
tissue inside a netted plastic enclosure (Netwell) that fits in the well while shaking. To
move the tissue quickly from one plate to another, you simply lift the netted enclosure
containing the tissue and move it to the next plate containing the appropriate solution.
Next, the specimen was labeled with the primary antibody, Doublecortin (Cell Signaling
Technology, Inc. #4604, rabbit). Primary antibody, raised in rabbit, was diluted 1:500 in
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1% blocking reagent and the tissue was transferred to a new 6-well plate to incubate on
the shaker for another 60 minutes at room temperature. Before being transferred into the
third plate of secondary antibody, the tissue went through (2) 10 minute washes with
PBS-Tween and a third 10-minute wash with HEPES/NaCl. After the washes, sections
were transferred to wells containing with biotinylated 2 antibody (anti-rabbit) and left on
the shaker to incubate at room temperature for 2 hours. The tissue was washed again,
twice for 10 minutes in PSB-Tween and once in HEPES/NaCl. Next, sections were
transferred to new wells and treated with the macromolecule complex, avidin and
biotinylated HRP, for the next 30 minutes on the shaker at room temperature. A final
rinse with PBS was performed before developing with Diaminobenzidine (DAB). The
DAB working solution was prepared per Vector Laboratories instructions (DAB substrate
kit for peroxidase, catalog # sk-4100). Specimens were incubated with gentle agitation at
room temperature until desired staining developed, which was normally 5 minutes or less.
The slices were washed well to remove any residual DAB and mounted on gel-subbed
slides, and allowed to dry. Once dried, the slides were dehydrated in a fume hood using
graded concentrations of ethanol and then xylene. Ethanol baths consisted of 5 minutes
each in 70%, 95%, 95%, 100%, 100%, and then (2) 5 minute baths in xylene.
Immediately following dehydration, DPX from Electron Microscopy Sciences was
applied across the sections and the slide was cover slipped. DPX is a hard mountant, fade
resistant, quick-drying made of distyrene, a plasticizer and xylene.

Microscopic Analysis
Slides were analyzed using a bright field microscope. Pictures of the DCX stained
area of the SVZ were taken of each hemisphere and scale bars were added to assist in
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later statistical analysis. To analyze the pictures, Image J (NIH) program was used. This
program allowed the DCX labeled area to be outlined and parameters to be set the same
for each image so the analysis was consistent. Each hemisphere had the DCX stained area
in 10 ventricles summed in m2 and converted to mm2 for statistical analysis.

Statistical Analysis
The treatment groups used for statistical analysis were control, simvastatin and
ascorbic acid, fluoxetine, and the combination of simvastatin, ascorbic acid and
fluoxetine. SPSS software was used for each statistical test. A one-way analysis of
variance (ANOVA) was performed to look for a difference between groups. A
Bonferroni post-hoc test showed where the differences were for each group. In order to
check for differences between the right and left sides of the brain, a two-way ANOVA
was done. To check for differences in weight at two different time points for the four
drug treatment groups, a repeated measures ANOVA was used. In addition, t-tests were
also used to check for significant differences between a treatment group and control.

Gene Analysis
Animals in the gene analysis group underwent the same protocol as the other rats
with regards to voluntary oral drug administration and distal middle cerebral artery
occlusion surgery. However, after brain removal, the tissue was quick-frozen in
isopropanol and dry ice and the frozen cortical samples were sent off to the CGR group,
at Wright State University, for genetic analysis. They then prepared RNA from the frozen
tissue, converted this into cDNA using a reverse transcriptase reaction, and then used the
cDNA to probe the rat gene chip
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RESULTS
Voluntary Oral Administration of Medication
For our primary study, we wanted to test four different post-stroke treatments for
their effects on neurogenesis. The drug treatments were control (vehicle), 0.5 mg/kg
simvastatin plus 20 mg/kg ascorbic acid; 5 mg/kg fluoxetine; or 5 mg/kg fluoxetine plus
0.5 mg/kg simvastatin plus 20 mg/kg ascorbic acid.
Since these treatments are oral medications by design, it would behoove us to find
a way to compel the animals to eat them. A challenge to this approach was making sure
the entire dose of medication was ingested. This required identifying a reliable vehicle for
administration that the rats would enjoy and consistently ingest in its entirety.
We tested a variety of foods without medication, on the Wistar rats. We left the vehicles
in the cages overnight and documented consumption amounts for each. After the data
were collected for each food, it was determined that Brunschweiger, sugar cookie dough,
peanut butter cookie dough and chocolate chip cookie dough (Pillsbury) were the most
successful vehicles. To narrow it down to one substance, we looked at ingredients, price
and ease to work with. Sugar cookie dough had a simpler ingredient list than the other
doughs, was cheaper than Braunschweiger and had a great consistency for mixing in the
dry medications. We also tried two different substances from animal food vendors, Napa
Nectar and Bio-Serv (transgenic dough), but the rats did not like either of them. Once we
started using the sugar cookie dough, the animals would normally consume it within
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30 minutes. For consistency purposes, we always left the Petri dishes in their cages
overnight.
We utilized this method of medication administration on a total of 79 rats, 24
Wistar males and 55 male and female Fishers, for a two-week period with considerable
reliability. There were only 5 times out of these 1106 times the rats were given the
vehicle or vehicle plus meds in this daily treatment, where an animal did not finish the
dough ball completely. This is a significantly high success rate of 99.5% (using equation
1106 complete consumption/1111 total feedings = .9954). The uneaten portions were
seen in each of the treatment groups, including the control, which leads us to believe it
was not the taste of the medications that discouraged the animals from finishing. Later,
16 female Fishers were administered their medication through the same method for 35
days with a 100% reliability rate. See Table 1.
Table 1 Drug ingestion reliability.
Incomplete drug ingestion incidents were noted when more than 100mg of cookie dough were found
in either the cage or Petri dish from the previous day.

Rat
Strain/(gender)

Incomplete
# of rats with
Number of # days of drug
drug ingestion incomplete
Reliability
Rats
administration
ingestion
incidents

Wistar (male)

24

14

1

1

99.70%

Fisher (male and
female)

55

14

4

3

99.48%

Fisher (female)

16

35

0

0

100%

The cookie dough method allowed for a simple and reliable means of
administering an oral medication to an animal without the nuisance of IP injections or
unnecessary stress on the rodent. However, the approach came with the added benefit of
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stabilizing the weight of the rats. It is normal for rats to lose 5-10% of their weight after a
sham stroke surgery and 17-20% after a stroke surgery using middle cerebral arterial
occlusion [79]. The cookie dough method allowed our rats to lose less weight than
average, maintain, or gain weight, as described in the next section.

Fisher Rats
The rats were retired breeders and around 1 year old. The females were from
Harlan, the three male Fishers were from Charles River, and although we do not have a
date of birth, we had asked for approximately the same age. Using rats that were a year or
more older would ensure the animal model represents realistic human scenarios and
translates well into clinical trials. Weights were recorded pre-surgery and one week postsurgery. Using the descriptive statistics in Table 2, a bar graph was created with the presurgery and post-surgery weight averages. The animals in group 2, receiving the
fluoxetine treatment, showed a 5% weight loss, or about 15 grams, which is on the low
end of normal for a sham surgery [79]. Group 3, treated with the fluoxetine combination
showed an average of 0.6% weight loss, while the other two Fisher rat groups were not
affected and actually showed a weight gain during the week following surgery. Figure 1
represents the Fisher rats’ weights, pre-surgery (solid bars) vs. post-surgery (striped bars),
which were taken one week later. The four different treatment groups are as follows:
Group 1, vehicle control- Group 2, 5mg/kg fluoxetine -Group 3, 5 mg/kg fluoxetine, 5
mg/kg simvastatin and 20 mg/kg ascorbic acid -Group 4, 5 mg/kg simvastatin and 20
mg/kg ascorbic acid. To look for differences between pre-surgery and post-surgery
among treatment groups, we analyzed the data using ANOVA. The results for this
ANOVA are shown in Table 3. There is a statistically significant interaction between
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Factor A (treatment) and Factor B (pre/post-surgery), with an interaction value of p =
0.002.
Table 2 Summary statistics for Fisher rats' weights

Average
Std
sqrt
s.e.

Control
Fluox
Fluox Combo
Statin Combo
Pre-Surge ry We ight Post-Surgery We igh Pre -Surgery We ight Post-Surge ry We ight Pre -Surgery We ight
Post-Surgery We igh Pre-Surge ry Weight Post-Surge ry We ight
420
430
417
377
341
339
256
257
315
320
259
252
290
291
253
256
250
256
251
241
263
264
256
256
265
267
251
244
254
245
261
269
260
270
283
271
279
279
275
273
282
278
268
256
281
276
298.667
303.500
288.167
273.500
285.400
283.600
263.667
264.500
58.114
60.049
58.658
47.282
30.467
31.683
10.546
7.797
2.449
2.449
2.449
2.449
2.236
2.236
2.449
2.449
23.725
24.515
23.947
19.303
13.625
14.169
4.305
3.183

Figure 10 Fisher rats' weights before and one week after surgery, divided into treatment
groups.
The four different treatment groups are as follows: Group 1, vehicle control- Group 2, 5mg/kg
fluoxetine- Group 3, 5mg/kg fluoxetine, 5mg/kg simvastatin and 20 mg/kg ascorbic acid- Group 4,
5mg/kg simvastatin and 20 mg/kg ascorbic acid
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Table 3 ANOVA Fisher rats' weights.
There is a statistically significant interaction between Factor A (treatment) and Factor B (pre/postsurgery). DF = degrees of freedom, SS = Sum of Squares, MS = Mean Square, F = F statistic, P = p
value

Source of Variation
Factor A
Subject(Factor A)

DF

SS

MS

3 8250.55 2750.19

F

P
0.606

0.619

19 86186.8 4536.15

Factor B

1

85.906

85.906

2.919

0.104

Factor A x Factor B

3 635.807 211.936

7.202

0.002

Residual

19

559.15

29.429

Total

45 95721.3 2127.14

Given the interaction between Factors A (treatment) and B (time) (p = 0.002), the
Holm-Sidak method was the post-hoc test used to assess all pairwise comparisons. Table
4 shows these statistics. There was no significance between any of the comparisons,
except the interaction between Factor B (pre and post-surgery weights) within the
fluoxetine treatment group (unadjusted p < 0.001). I showed evidence in the Introduction
that fluoxetine treatment often leads to weight loss.
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Table 4 Fisher: Holm-Sidak post-hoc method for multiple comparisons.
There was no significance between any of the comparisons, except the interaction between Factor B
within the fluoxetine treatment (unadjusted p < 0.001).

Factor B within Control
Comparison
Post vs. Pre

Diff of Means
4.833

t
1.543

Unadjusted P
0.139

Critical Level
0.050

Significant
NO

Factor B within Fluox
Comparison
Post vs. Pre

Diff of Means
14.667

t
4.683

Unadjusted P
<0.001

Critical Level
0.050

Significant
YES

Factor B within Fluox combo
Comparison
Diff of Means
Post vs. Pre
1.8

t
0.525

Unadjusted P
0.606

Critical Level
0.050

Significant
NO

Factor B within Statin
Comparison
Post vs. Pre

Diff of Means
0.667

t
0.213

Unadjusted P
0.834

Critical Level
0.050

Significant
NO

Factor A within Pre
Comparison
Control vs. Statin
Fluox vs. Statin
Fluox Combo vs. Statin
Control vs. Fluox Combo
Control vs. Fluox Combo
Fluox vs. Fluox Combo

Diff of Means
34.833
24.333
21.567
13.267
10.5
2.767

t
1.263
0.882
0.745
0.459
0.381
0.0956

Unadjusted P
0.222
0.389
0.465
0.652
0.708
0.925

Critical Level
0.009
0.010
0.013
0.017
0.025
0.050

Significant
NO
NO
NO
NO
NO
NO

Factor A within Post
Comparison
Control vs. Statin
Control vs. Fluox
Control vs. Fluox Combo
Fluox Combo vs. Statin
Fluox Combo vs. Fluox
Fluox vs. Statin

Diff of Means
39.000
30.000
19.900
19.100
10.100
9.000

t
1.414
1.088
0.688
0.66
0.349
0.326

Unadjusted P
0.173
0.29
0.5
0.517
0.731
0.748

Critical Level
0.009
0.010
0.013
0.017
0.025
0.050

Significant
NO
NO
NO
NO
NO
NO
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Wistar Rats
The male Wistar rats, which came from Charles River, weighed 500-750 grams.
This 250-gram range accounts for much of the range in the error bars. We do not have a
date of birth for these rats, but they were retired breeders and we requested rats 10-12
months old when we ordered them. Unlike the Fisher rats, the Wistar’s post-surgery
weights were compared at one week and two weeks with summary statistics found in
Table 4. The Wistar rats in group 4 received the statin combo treatment and lost the most
weight the first week after surgery with an average of 14g or 2.3%. The second week they
began to regain the weight. Groups 1 (control) and 3 (Fluoxetine combo treatment) lost
10.83g and 10.66g, respectively, in the first week. In the second week, the control group
began to regain the weight, however group 3 lost a little more. The total amount of
weight lost in group 3 averaged 13.6g that is only 2% and appreciably below the average
range of 5-10%. Group 2 (Fluoxetine treatment) had the least weight loss at 0.5% (3.5g)
on average and began to regain the weight in the second week after surgery. A bar graph
of these weight averages can be found in Figure 11. The solid bars indicate pre-surgery
weights, while the striped bars represent 1-week post-surgery and the crossed bars are 2
weeks post-surgery.
Table 5 Summary statistics for Wistar rats' weights
Control

Fluox

Fluox Combo

Statin Combo

pre

post

post

pre

post

post

pre

post

post

pre

post

post

734

718

720

724

723

716

687

660

661

552

550

545

680

656

665

635

635

643

675

665

662

750

730

733

702

690

699

549

535

543

629

623

616

686

675

674

599

595

604

642

636

640

586

592

592

592

570

576

585

583

581

524

513

520

698

694

685

527

525

530

515

508

519

629

640

651

642

619

619

536

509

520

Average

635.830

625.000

631.330

617.170

613.670

618.833

652.830

642.170

639.170

607.170

593.170

596.330
79.567

Std

75.836

70.932

70.087

65.593

70.620

67.115

38.408

34.027

32.318

83.047

81.190

sqrt

2.449

2.449

2.449

2.449

2.449

2.449

2.449

2.449

2.449

2.449

2.449

2.449

s.e.

30.960

28.958

28.613

26.778

28.831

27.400

15.680

13.891

13.194

33.904

33.146

32.483
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Figure 11 Wistar rats' weights before surgery, one week post, and two weeks post-surgery.
The four different treatment groups are as follows: Group 1, vehicle control- Group 2, 5mg/kg
fluoxetine- Group 3, 5mg/kg fluoxetine, 5 mg/kg simvastatin and 20 mg/kg ascorbic acid- Group 4,
5mg/kg simvastatin and 20 mg/kg ascorbic acid.

In order to check for differences and interactions among treatments and weights, a
Repeated Measures ANOVA, comparing treatment groups (Factor A) with pre-surgery
weight, one week post-surgery weight and two weeks post-surgery weight, indicates that
there is a significant difference in the mean values among the different levels of Factor B
(weights over time) (p < 0.001). This is shown in Table 6. To distinguish which groups in
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Factor B were significantly different from one another, we ran a post-hoc test for multiple
comparisons, using the Holm-Sidak Method, once again. In Table 7, you can see the
results from this test.
After making all pairwise comparisons between pre/post-surgery weights,
independent of treatment, it was found that the pre-weights were significantly different
from the post weights in both week one (unadjusted p < 0.001) and two (unadjusted p <
0.001). However, post-surgery weights in weeks one and two did not differ significantly
from each other.
Table 6 A repeated measures ANOVA, Wistar rats' weights.
The repeated measures ANOVA, comparing pre-surgery weights to one-week post-surgery and again
to weights two weeks post-surgery. Factor A is treatments, while Factor B is pre/post-surgery
weights. DF = degrees of freedom, SS = Sum of Squares, MS = Mean Square, F = F statistic, P = p
value There is a significant difference in the mean levels of Factor B (p < 0.001).

Source of
Variation

DF

SS

MS

F

P

Factor A

3

20773

6924.33

0.438

0.728

Subject
Factor A

20

316384 15819.2

Factor B

2

1202.11 601.056 15.708

<0.001
0.064

Factor A x
Factor B
Residual

6

502.667 83.778

40

1530.56 38.264

Total

71

340392 4794.26

41

2.189

Table 7 Wistar: Holm-Sidak for multiple comparisons.
Factor B, pre/post surgeries, (significance level 0.05); Independent of treatment, the pre-weights were
significantly different from the post weights in both week one (unadjusted p < 0.001) and two
(unadjusted p < 0.001).

Comparisons for Factor B
Comparisons
Pre vs. Post 1
Pre vs. Post 2
Post 2 vs. Post 1

Diff of Means
9.75
6.833
2.917

t
Unadjusted P Critical Level Significant
5.46
<0.001
0.017
YES
3.827
<0.001
0.025
YES
1.633
0.110
0.05
NO

The weight comparison between pre and post-surgery was important to analyze
because weight has been a long-standing parameter associated with health in laboratory
experiments [80]. As shown in the table below, the largest weight loss across all
treatments was still at the low end of the normal range of 5-10% for sham surgeries. All
other weight loss was below this normal range.
Table 8 Fisher rats and Wistar rats total weight loss with each treatment.
FISHER
CONTROL
FLUOX
FLUOX +
STATIN

Not affected: weight gain week following surgery
15g loss: 5%: low end of normal for sham
0.6% loss: considerably below average
Not affected: weight gain week following surgery

WISTAR
CONTROL
FLUOX
FLUOX +
STATIN

10.83g loss: Weight gain week 2
3.5g loss: 0.5%: Weight gain week 2
13.6g loss total: 2%: below average loss
14g loss: 2.3%: Weight gain week 2

Doublecortin Expression in SVZ Indicative of Neurogenesis
The primary interest of this study was the effect of three different drug treatments
on neurogenesis after induced stroke through distal MCAO, in aged rodents. After
examining the brains post-surgery, we were unable to find any evidence of large brain
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infarcts, so it was apparent the distal MCA had not been occluded successfully. We
therefore treated all of the surgery animals as sham stroke surgery animals. This study
changed to investigate the effects of these treatments on neurogenesis and gene
expression on sham stroke surgery animals. Fluoxetine (5mg/kg), simvastatin (0.5
mg/kg) plus ascorbic acid (20 mg/kg) and a combination treatment of fluoxetine,
simvastatin and ascorbic acid (5mg/kg, 0.5mg/kg, 20mg/kg, respectively) were tested
against control (no treatment).
For two weeks, male Wistar rats, which were at least 1 year old, were
administered one of these drug treatments or control, utilizing the cookie dough method.
All rats voluntarily ingested their cookie dough balls. To measure neurogenesis we used a
Doublecortin antibody to stain newborn, migrating neurons in the anterior lateral
ventricles of the subventricular zone (SVZ) and a horseradish peroxidase labeled
secondary antibody, using DAB as a substrate. We used images taken with a bright field
microscope equipped with a digital SPOT camera to view the neurogenesis accentuated
by the Doublecortin/DAB staining. The visual results of this staining can be seen on the
tissue sections in Figure 12, while the summary statistics for the mean area of
neurogenesis with hemispheres combined, is shown in Table 9. In Figure 12, it is visually
apparent that the largest and most dense area of neurogenesis existed in the
fluoxetine/statin/ascorbic acid combination treatment group.
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Figure 12 Neurons in the lateral ventricles of the subventricular zone, stained with Doublecortin
antibody.
There is a tiny increase in neurogenesis from control (panel A) following treatment with simvastatin
(panel B). In panel C is the 11-fold increase in mean area of staining with Doublecortin after
treatment with fluoxetine. The largest increase can be seen in panel D, representing the 19-fold
increase in area of staining after the combination treatment fluoxetine, simvastatin and ascorbic acid.

Table 9 Summary statistics for the mean area of neurogenesis in mm2

Using the summary statistics from Table 9, we created a histogram with the mean area
of neurogenesis. This graph, Figure 13, demonstrates that the biggest difference in mean
area of neurogenesis occurred following treatment with the drug combination of
fluoxetine, simvastatin and ascorbic acid. Comparing the fluoxetine group with control,
we observed an 11-fold increase in neurogenesis and when comparing the statin group
with control, there was a 1.4 fold change. The most significant finding was the 19-fold
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increase in mean area of neurogenesis that we found with the fluoxetine combination
treatment when compared to control.

Figure 13 Histogram showing the mean area of neurogenesis for each treatment with hemispheres
combined.
When comparing the means of the control group and the fluoxetine treatment group, we note a 10fold change in the mean area of neurogenesis. The most significant result was the comparison
between the control group and the fluoxetine combination treatment group with a noteworthy 19fold increase in neurogenesis.

We tried to run a one-way analysis of variance with the hemispheres combined,
using data in mm2, but the Shapiro-Wilk normality test (p<0.050) as well as the equal
variance test (p<0.050) failed. In order to analyze the data, we ran a Kruskal-Wallis oneway analysis of variance on ranks. The results for this one-way ANOVA for treatments
on combined hemispheres are summarized in Table 10. The differences in the median
values among the treatment groups were greater than expected by chance and statistically
significant. The H statistic = 12.734 with 3 degrees of freedom (p = 0.005). A Dunn’s
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multiple comparisons test, shown in Table 11, isolated the fluoxetine combination group
vs control as statistically significant (p < 0.05).
Table 10 Kruskal-Wallis one-way ANOVA for combined hemispheres.
Median area of neurogenesis stained by Doublecortin measured in mm2. H = 12.734, with 3 degrees of
freedom (p = 0.005). The ‘N’ is the number of animals in each group. Each animal represents
summed staining in 10 coronal slices from the SVZ for each hemisphere.

Group
Control
Statin
Fluoxetine
Fluoxetine

N
3
4
5
4

Missing Median
0
0.0489
0
0.0769
0
0.579
0
1.015

25%
0.042
0.0574
0.0491
0.642

75%
0.0615
0.0812
0.652
1.246

Table 11 All pairwise multiple comparison procedures using Dunn’s Method.
The Fluoxetine combination group vs Control was significant, p < 0.05.

Comparison

Diff of Ranks

Fluox combo vs Control
Fluox Combo vs Statin
Fluox Combo vs Fluoxetine
Fluoxetine vs Control
Fluoxetine vs Statin
Statin vs Control

11.417
8.5
3.15
8.267
5.35
2.917

Q

P < 0.05

3.14
Yes
2.525
No
0.986 Did not test
2.378
No
1.675 Did not test
0.802 Did not test

We analyzed these results again with the same tests, but this time but the data
were given in µm2. Tables 12 and 13 show these results. The H statistic changed from H
= 12.734 with 3 degrees of freedom (p = 0.005) to H = 14.029 with 3 degrees of freedom
(p = 0.003). The differences in medians among treatment groups were still greater than
expected by chance. However, when looking at Dunn’s Method in Table13, there are two
groups identified as statistically significant: Fluoxetine combination vs. Control and
Fluoxetine combination vs. Statin (p < 0.05). By increasing the range of numbers being
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analyzed when we moved from mm2 to um2, we added sensitivity to the statistical
analysis.
Table 12 Kruskal-Wallis one-way ANOVA for combined hemispheres.
Median area of neurogenesis stained by Doublecortin measured in µm2. H = 14.029, with 3 degrees of
freedom (p = 0.003). The ‘N’ is the number of animals in each group. Each animal represents 10
coronal slices from the SVZ for each hemisphere.

Group
Control
Statin
Fluoxetine
Fluox
Combo

N
3
4
5

Missing
0
0
0

Median
48875.670
76585.865
590493.800

25%
42022.610
62737.952
528371.200

75%
61409.850
92530.747
613099.350

4

0

939336.700

731882.850

1212541.625

Table 13 All pairwise multiple comparison procedures for combined hemispheres using Dunn’s
Method.
The Fluoxetine combination group vs Control was significant, p < 0.05 in addition to Fluoxetine
combination group vs Statin group, p < 0.05.

Comparison

Diff of Ranks

Q

P < 0.05

Fluoxetine + vs Control
Fluoxetine + vs Statin

12.5
9

3.438
2.673

Yes
Yes

Fluoxetine + vs Fluoxtine
Fluoxetine vs Control
Fluoxetine vs Statin
Statin vs Control

4.5
8
4.5
3.5

1.409
2.301
1.409
0.963

No
No
Did not test
Did not test

Next, we analyzed the results by hemisphere. The summary statistics in mm2,
separated by hemisphere, can be found in Table 14. These data failed the Shapiro-Wilk
normality test (p < 0.050) and the equal variance test (p < 0.050). In order to look for a
difference among the means of these data, a two-way analysis of variance was calculated
(Table 15) utilizing the Kruskal-Wallis Method. Factor A represents the different
treatment groups and the results indicate a significant difference among the groups with p
< 0.001. This two-way ANOVA also tested the difference in mean values with respect to
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hemispheres (Factor B) and concluded that there is not a statistically significant
difference (p = 0.408). The results for the interaction between the two factors, treatment
and hemisphere, showed no statistical significance (p = 0.866).
To isolate the differences among the treatment groups (Factor A) a multiple
comparisons test was performed. The Holm-Sidak method was used with an overall
significance level of 0.05. All comparisons for Factor A can be seen in Table 16. The
only group found to be not statistically significant was the statin vs. control (unadjusted p
= 0.826). The other five comparisons were all found to be significant with unadjusted p
values < 0.001. A graph of each treatment group, separated into hemispheres, can be seen
in Figure 14.
Table 14 Summary statistics of area, separated by hemisphere, measured in mm2

Side

Group
Control
Statin
Fluoxetine
Fluoxetine Combo

Left
Right
Left
Right
Left
Right
Left
Right

Mean

N

Std. Deviation

Min

Max

0.027
0.024
0.035
0.037
0.264
0.308
0.453
0.515

3
3
4
4
5
5
4
4

0.007
0.006
0.013
0.008
0.041
0.075
0.141
0.179

0.019
0.018
0.021
0.030
0.215
0.194
0.274
0.299

0.031
0.031
0.051
0.045
0.327
0.370
0.600
0.668
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Table 15 Two-Way ANOVA for separated hemispheres using the Kruskal-Wallis Method.
Factor A is treatments, Factor B represents hemispheres. DF = degrees of freedom, SS = Sum of
Squares, MS = Mean Square, F = F statistic, P = p value. There is a significant difference among
means of the treatment groups, p< 0.001.

Source of Variation

DF

Factor A
Factor B
AxB
Residual
Total

SS
3
1
3
24
31

1.098
0.005
0.006
0.186
1.297

MS

F

0.366
0.005
0.002
0.008
0.042

P
47.263 < 0.001
0.708
0.408
0.243
0.866

Table 16 Holm-Sidak method for multiple comparisons on separated hemispheres for Factor A,
Treatment

Comparison
Fluox Combo vs Statin
Fluox Combo vs Control
Fluoxetine vs Statin
Fluoextine vs Control
Fluox Combo vs Fluoextine
Statin vs Control

Diff of
Means
0.448
0.458
0.25
0.261
0.197
0.0106

t
10.18
9.644
5.998
5.742
4.729
0.222

Unadjusted
P
<0.001
<0.001
<0.001
<0.001
<0.001
0.826

Critical
Level
0.009
0.01
0.013
0.017
0.025
0.05

Significant?
YES
YES
YES
YES
YES
NO

Figure 14 Mean area of neurogenesis separated by hemisphere and treatments.
Seventy-nine rats were treated with Fluoxetine (5mg/kg), simvastatin (0.5 mg/kg) plus ascorbic acid
(20 mg/kg), a combination treatment of fluoxetine, simvastatin and ascorbic acid (5mg/kg, 0.5mg/kg,
20mg/kg, respectively) or no treatment (control). After MCA occlusion, neurogenesis was measured
by staining newborn, migrating neurons with Doublecortin. Since there was no infarct induced, there
is no significant difference shown between the hemispheres.
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Gene Analysis Results
Neither Simvastatin nor Fluoxetine were originally designed to increase
neurogenesis. It is likely that these drugs are working in a way outside of their normal
mechanism of action and something about the combination of the simvastatin and
Fluoxetine caused a synergistic increase in neurogenesis. In order to determine how these
drugs may have been working in the brain, we isolated cortical tissue from animals with
each of the drug treatments, rapidly froze the tissue and provided it to the Genomics
Research Center for analysis of gene expression using the Rat Gene Chip. We provided a
large portion of the cortex and allowed the Genomics Research Center to choose a
smaller portion to analyze. In hindsight, we now know that we should have concentrated
on regions near the Subventricular zone of the Lateral Ventricles, as growth factors are
concentrated in this region. We would have seen more gene changes with respect to these
growth factors if we had isolated the subventricular zone for analysis. Dr. Markey
isolated RNA from the tissue, then used this RNA to reverse transcribe cDNA. Rat Gene
Chips were probed with the cDNA of the different treatment groups. Performing the gene
chip analysis allowed us to leverage the wealth of knowledge available to researchers in
the Gene Ontology database. This automated analysis helps to identify patterns within
groups of genes and to ascribe a biological meaning to the expression. Correlating
biological meaning with specific genes or gene groups and combing that knowledge with
experimental research allows scientists to make inferences that are well-supported about
possible mechanisms of action that support the increase in neurogenesis. Unfortunately,
we performed this experiment in the early days of gene chip analysis and the software
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could not identify specific genes unique to each drug treatment compared to control. We
were limited to analysis tools available at that time, which gave us incomplete data.
A microarray Gene Ontology analysis was performed to identify genes that were
up-regulated and down-regulated with respect to each of the treatments. These genes
become of particular importance because if we can manage them through various
treatments we are closer to mitigating the response to trauma. Expression results in
entirety can be found in Appendix A.
The microarray analyses uncovered 14 up-regulated genes (>2 fold change,
p<0.05) in fluoxetine treatment versus vehicle. There were 5 up-regulated genes (>2 fold
change, p<0.05) in Fluoxetine combination treatment versus vehicle. We found 31 upregulated genes (>2 fold change, p<0.05) in statin/ascorbic acid treatment versus vehicle,
and 30 down-regulated genes (>2 fold change, p<0.05) in fluoxetine combination
treatment versus statin/ascorbic acid treatment (Table 17-20).
Within the fluoxetine treatment versus vehicle, profiling of the up-regulated genes
showed genetic themes largely involved in molecular functions for channel activity (10
genes, p<0.05). Genetic themes largely involving biological processes and reactions for
clotting activity (5genes, p<0.05) were found when profiling the up-regulated genes for
the fluoxetine combination treatment versus vehicle. When profiling was done for the
statin/ascorbic acid treatment versus vehicle, there were 31 up-regulated genes showing
the largest genetic trend towards the biological process for immune response (14 genes,
p<0.05). Other genetic themes included cascades, signaling and pathways. In the
fluoxetine combination treatment versus statin/ascorbic acid treatment profiling analysis
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revealed a trend towards biological process for immune response (19 genes, p<0.05)
within a group of 30 down-regulated genes (Table 17-20*).

Gene Ontology Analyses
There are many ways to analyze gene results, however since our most significant
results came from the two fluoxetine treatment groups, we looked at the data within these
groups for comparison. Transcription factors are regulators of gene expression. Some
interesting gene ontology results were found when transcription factor targets were
merged and analyzed. Both the fluoxetine versus vehicle and the fluoxetine combination
treatment versus vehicle targeted gene sets for Foxa1 (forkhead box A1), also called
HNF-3a (hepatocyte nuclear factor 3 alpha) and Hif1a (Hypoxia inducible factor 1a) (upregulated >2 fold change, p<0.05). In the discussion, we will show that Hypoxia
inducible factor has been regulated by Fluoxetine in other animals following stroke, so
the changes here are not unprecedented. These genes were produced by interactions of
the U2 and U6 small nuclear RNA segments of the nuclear spliceosome either
exclusively or with Transthyretin (Ttr) Table 21.
When we examined the results of the simvastatin/ascorbic acid treatment group
versus vehicle we found that the differentially expressed genes up-regulated with a >2
fold change (p<0.05) belonged to mostly to the ontology of biological processes. Most
importantly, the biological processes are involved in transport, regulation and response
shown in Table 22.
Within this same comparison, the simvastatin/ascorbic acid treatment group
versus vehicle, we identified the differentially expressed genes, Alpha-2-macromolecule
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(A2m), protein kinase delta (Prkcd), Sclerostin Domain Containing 1 (Sostdc1), which
are common to a variety of signaling pathways, shown in Table 23.
Table 17 . Fluoxetine Treatment vs. Vehicle, genes upregulated >2 fold, p<0.05.
Genetic trend towards channel activity*
GO Term ID Term type

Term name

p-value

35068

CC

micro-ribonucleoprotein complex

1.65E-02

22803

MF

passive transmembrane transporter activity

2.96E-02

15267
22836

MF
MF

*channel activity
*gated channel activity

2.96E-02
3.43E-02

22832

MF

*voltage-gated channel activity

2.14E-02

22838

MF

*substrate-specific channel activity

2.02E-02

5216

MF

*ion channel activity

1.66E-02

22839

MF

*ion gated channel activity

3.43E-02

5244

MF

*voltage-gated ion channel activity

2.14E-02

5261

MF

*cation channel activity

2.48E-02

22843

MF

*voltage-gated cation channel activity

3.81E-03

8332

MF

*low voltage-gated calcium channel activity

1.83E-04

KEGG:04020
KEGG:04930

ke
ke

Calcium signaling pathway
Type II diabetes mellitus

2.75E-03
8.46E-03

Table 18 Fluoxetine Combination Treatment vs. Vehicle, genes upregulated >2 fold, p<0.05.
Lowest p-values for genetic trend are biological processes for cell fate roles*
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Table 19 Statin/Ascorbic acid Treatment vs. Vehicle, genes upregulated >2 fold, p<0.05.
Genetic trend towards biological processes associated with immunity*
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Table 20 Fluoxetine Combination Treatment vs. Statin/Ascorbic acid Treatment, genes downregulated >2 fold, p<0.05. Genetic trend of biological processes for immunity*

Table 21 Fluoxetine vs Vehicle and Fluoxetine Combination vs Vehicle Treatment group, merged
transcription factor targets up-regulated 2 fold, p<0.05.
Treatment Group

Gene Set Gene Symbol

Fluox vs Vehicle

Foxa1

U2|U6

U2 spliceosomal RNA|U6 spliceosomal RNA

Fluox vs Vehicle

Hif1a

U2|U6

U2 spliceosomal RNA|U6 spliceosomal RNA

Fluox Combo vs vehicle

Foxa1

Ttr|U2|U6

Transthyetin|U2 spliceosomal RNA

Fluox Combo vs vehicle

Hif1a

U2|U6

U2 spliceosomal RNA|U6 spliceosomal RNA
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Table 22 Gene ontology of Simvastatin/Ascorbic acid Treatment group vs. Vehicle, >2 fold change, p
< 0.05.

Table 23 Upregulation 2.0 fold change, in Simvastatin/Ascorbic acid Treatment group versus
Vehicle.
The differentially expressed genes are identified as A2m, Prkcd, Sostdc1, looking at common
pathways, p < 0.05
Gene-Set Name

Gene Symbols

mTOR signaling pathway

A2m|Prkcd|Sostdc1

Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling A2m|Prkcd|Sostdc1
Signaling events mediated by focal adhesion kinase

A2m|Prkcd|Sostdc1

S1P1 pathway

A2m|Prkcd|Sostdc1

PDGFR-beta signaling pathway

A2m|Prkcd|Sostdc1

Internalization of ErbB1

A2m|Prkcd|Sostdc1

Insulin Pathway

A2m|Prkcd|Sostdc1

ErbB1 downstream signaling

A2m|Prkcd|Sostdc1

EGF receptor (ErbB1) signaling pathway

A2m|Prkcd|Sostdc1

Class I PI3K signaling events mediated by Akt

A2m|Prkcd|Sostdc1

Class I PI3K signaling events

A2m|Prkcd|Sostdc1

Arf6 trafficking events

A2m|Prkcd|Sostdc1

Arf6 signaling events

A2m|Prkcd|Sostdc1

Arf6 downstream pathway

A2m|Prkcd|Sostdc1

EGFR-dependent Endothelin signaling events

A2m|Prkcd|Sostdc1

IGF1 pathway

A2m|Prkcd|Sostdc1

IL5-mediated signaling events

A2m|Prkcd|Sostdc1

GMCSF-mediated signaling events

A2m|Prkcd|Sostdc1

PDGF receptor signaling network

A2m|Prkcd|Sostdc1

Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) A2m|Prkcd|Sostdc1

56

DISCUSSION
Voluntary Oral Administration of Medication
The most uncomplicated method of giving animals their drug treatments is hiding
the medication in a food or liquid. Currently, the most popular methods of administration
are oral gavage, IP injections and IM injections, depending upon the medication and
study [81]. Finding a better solution would benefit the scientific community, as it would
reduce stress in the animal model in administration of daily medicines.
The gavage procedure involves manually restraining a conscious animal, insertion
of a small tube down the esophagus into the stomach and administration of the treatment
drug into the tube via syringe [82]. This procedure brings with it many issues as each step
in the process can induce stress in the animal. The stress response is linked to the plasma
corticosterone (pCORT) level and it has been shown that this measurement parallels the
animals heart rate during/after it has been subjected to the stressor [83]. Stressors for the
rodent have been recognized as different types of restraint, injections, cage cleaning and
excessive handling [83]. These stressors have also been shown to span both male [84]
and female [85] populations. Results from a study analyzing stress related to oral gavage
in 2005, showed that the stress response related to the procedure could last for 30-60
minutes afterwards [86].
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Intraperitoneal injections necessitate restraining of the animal, belly-up and
delivering the medication directly into the peritoneum via syringe. This method is not
perfect, as the success rate depends highly upon precision. For instance, it is common
forsome of the treatment to be delivered into the gut, subcutaneous tissue or belly fat,
therefore the full dose of medicine would not be delivered to the animal’s circulation
[87].
Giving an intramuscular injection can be tricky because the muscle mass is so
small in rodents and the animal will need to be well restrained. Because of their small
size, rodents can usually only receive treatments of 0.05ml or less. Additionally,
discomfort can be caused by injecting material that is not body temperature or has too
high/low of a pH [87].
A study focusing on both IM and IP injections by Morton et al 2001 showed that
the pattern of heart rate recovery following both types of injections indicated that IP
injections were more stressful than IM injections and likely, more painful [88]. Variables
such as technician experience, volume, temperature of the fluid and pH make it difficult
to standardize these processes [83].
Due to the many nuances associated with these most popular methods,
investigators have researched voluntary oral administration alternatives. In 2002,
scientists tried using pre-mixed drug chocolate pellets and while they found this method
effective for use with a large number of rats over an extended period, there were several
drawbacks [89]. The theobromine and caffeine contained in the mixture may not be
conducive to mixing with certain drugs or could interfere with the study results. In
addition, the drug of choice must possess the proper consistency for mixing with the
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chocolate and the taste should be somewhat disguised to the animal [89]. In our protocol,
the fluoxetine was still bitter in the mixture, but it seemed that the animals enjoyed the
cookie dough enough to fully consume the dosage in spite of it.
Other scientists have tried sucrose solutions with neuroleptic drugs [90] given to
the animals by syringe which they drank from voluntarily as well as sucrose solutions
with donepezil and galantamine used for the treatment of Alzheimer disease [82].
Although scientists have been able to get the animals to drink voluntarily from the
syringe, there are limitations associated with the practice. For example, there is a learning
curve of roughly 3 days to teach the animals. Likewise, the actual procedure itself can be
time-consuming especially if you are utilizing a large number of animals in the study.
Only specific medications can be dispensed this way because some do not dissolve into
solution and may have to be administered in suspension [82].
We have demonstrated a reliable method for laboratory rats to voluntarily ingest a
fixed dose of dry drug treatment. We delivered individually measured dry drugs inside of
a 4 gm ball of sugar cookie dough daily to our animals. This approach addresses the
plethora of shortcomings found in previous studies:
1. The learning curve: Rats enjoyed the sugar cookie dough vehicle so much, they
were immediately drawn to it
2. Disguising the taste: Fluoxetine is very bitter and the taste of the cookie dough
was enough to make them continue eating it
3. Inability to use suspension medications: Most suspension medications can be
administered in dry form
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4. Time-consumption due to lengthy interaction with each animal: With our method,
the animal does not need to be supervised during administration.
With stress being such a significant factor in the past, we wanted to find a way to
overcome that. Because our drug delivery occurred in the animals’ own cage and there
was no handling or restraint necessary, the animals looked forward to their treatments.
The rats were housed individually to be sure they ingested their entire dose of
medication, removing variability in the data due to pain and or stress. Additionally, we
showed that this dosing could be performed over an extended period, up to 5 weeks in
this case, and with both Wistar and Fisher strains of rat. A disadvantage to utilizing the
Cookie Dough Method would be the unsuitability for a diabetic rat model.
The second component to the oral dosing study was monitoring the weight of the
animals. Since weight maintenance is regularly associated with health in laboratory
experiments, it was a goal of ours to design a drug treatment method that would allow the
animals to remain calm enough to eat regularly and not lose weight during the study. As
shown in the results, in Table 8, the weight loss of our animals was at the low end of
normal (5-10% for sham surgeries) or smaller.
Overall, we believe we have found an effective and reliable method to administer
drug treatments to two different strains of rats over a prolonged period, of up to 5 weeks
that eliminates the stress and time-consuming processes associated with IP and IM
injections and oral gavage.

Doublecortin Expression in SVZ Indicative of Neurogenesis
We compared the three chosen drug treatments with control, after surgery, but in
the absence of stroke. Before the surgeries, we performed functional tests using the
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modified Neurological Severity Score, Table 24 [91] and collected baseline data, which
did not differ from the data collected after the surgeries. It was the combination of these
data and the lack of an infarct seen after brain dissection that required us to examine the
impact of our drug treatments exclusive of stroke, treating all animals as sham surgery
animals.
Table 24 Scoring for the mNSS test.
The higher the score, the worse the deficit is. Our baseline data did not differ from the data we collected after
the surgeries, indicating that there was no functional deficit.
Neurological Severity Scores (NSS)
Points
Motor tests
Raising rat by the tail
1 Flexion of forelimb
1 Flexion of hindlimb
1 Head moved >10° to vertical axis within 30 s
Placing rat on the floor (normal=0; maximum=3)
0 Normal walk
1 Inability to walk straight
2 Circling toward the paretic side
3 Fall down to the paretic side
Sensory tests
1 Placing test (visual and tactile test)
2 Proprioceptive test (deep sensation, pushing the paw
against the table edge to stimulate limb muscles)
Beam balance tests (normal=0; maximum=6)
0 Balances with steady posture
1 Grasps side of beam
2 Hugs the beam and one limb falls down from the beam
3 Hugs the beam and two limbs fall down from the
beam, or spins on beam (>60 s)
4 Attempts to balance on the beam but falls off (>40 s)
5 Attempts to balance on the beam but falls off (>20 s)
6 Falls off: No attempt to balance or hang on to the
beam (<20 s)
Reflexes absent and abnormal movements
1 Pinna reflex (head shake when touching the auditory
meatus)
1 Corneal reflex (eye blink when lightly touching the
cornea with cotton)
1 Startle reflex (motor response to a brief noise from
snapping a clipboard paper)
1 Seizures, myoclonus, myodystony
Maximum points

3

3

2

6

4

18

One point is awarded for the inability to perform the tasks or for the
lack of a tested reflex; 13 to 18 indicates severe injury; 7 to 12,
moderate injury; 1 to 6, mild injury.
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We used Doublecortin antibody to label the newly dividing neurons, isolated the
specific area of neurogenesis in the anterior subventricular zone of the lateral ventricles
and compared the area of neurogenesis of each treatment in um2. Our results had two
significant findings and both were with fluoxetine. Fluoxetine vs Control showed a 10fold increase in neurogenesis, while the fluoxetine combination treatment exhibited a 19fold increase in the mean area of neurogenesis for combined hemispheres.
One neuroscience study showed no change in Brd-U labeling after fluoxetine
treatment for one week, however when maternally separated rats were treated with
fluoxetine for a week, the amount of apoptotic cells decreased [92]. These studies
focused on the dentate gyrus (DG), also known for continued neurogenesis into
adulthood, but located considerably more caudal than the area we were examining.
Research has still not been able to determine which cells (stem or progenitor cells) in the
DG are targeted by the fluoxetine treatments [93]. Additionally, both studies utilized
injections for treatment administration.
Injections could have an effect on drug study results due to the interaction of the
drug and glucocorticoids. Glucocorticoids (stress hormones) play a huge role in
neurogenesis. Removal of the adrenal gland in rats, leads to an increase in proliferation of
stem cells or progenitor cells, but when glucocorticoids are high, the formation and
survival of progenitor cells is decreased [94]. A study using blood samples indicated that
diurnal rhythms have an impact on corticosterone (stress hormone) levels of both male
and female rats [95]. The diurnal rhythm guides the rhythm of the progenitor cells [96].
Additionally, corticosterone performs a gate-like function with fluoxetine, so that if the
diurnal rhythm is altered, proliferation as a result of fluoxetine will be altered, as well
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[96]. When the diurnal rhythm is flattened, as seen in depressed patients, fluoxetine
seems to have less influence on cell proliferation [96]. The study showed strain
differences when comparing Lister Hooded (LH) and Sprague Dawley (SD) rats: the LH
rats, which have a naturally more flattened diurnal rhythm, had a lower progenitor cell
count. Having a stress free method of administering our treatment helped protect against
any impact that stress hormone could have had on our experiment. We know that time of
administration does not affect the results of fluoxetine [97], as fluoxetine has the same
effect whether it is taken at night or in the morning. It has also been shown that although
rats are nocturnal, administering the medication during the day would most likely not
cause any issues. At times, rats modify their activity pattern for survival [98], and this
includes eating during the day. Additionally, there was no obligation for the rats to eat
their medication during the day. We left the cookie dough balls in the cages overnight so
they could eat it whenever they wanted and while most rats woke up to eat the dough
right away, the occasional rodent would eat it later. For other drugs, timing of medication
doses may influence results, but because the effects of fluoxetine are cumulative, timing
did not matter for our study.
We believe that low stress levels kept glucocorticoids from interfering with the
experimental treatments. The differences between means and medians increased in the
following order: Control, Statin, Fluoxetine, Fluoxetine combination. This is as expected
from the visual observations of neurogenesis, as well as the histogram seen in Figures 3
and 4, respectively.
Our results suggest that fluoxetine and fluoxetine combined with simvastatin play
large roles in neurogenesis and could possibly be influencing various pathways. For
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instance, since glucocorticoid levels do not seem to be a factor in our study, there does
not seem to be any long-lasting effects of stress on our test animals and therefore the
natural effects of fluoxetine may have manifested through increased neurogenesis.
The glucocorticoid receptor is the main mediator of stress response in
neurogenesis and neuronal progenitor cells in mammals. It also plays a role in migration
and functional integration of newborn born neurons [99]. When a mammal is stressed, it
must exhibit physiological and behavioral changes in order to recover to homeostasis. It
does not matter in what form the stress presents itself, as the physiological response
remains predictable [100]. The entire response is orchestrated by the HypothalamusPituitary-Adrenal (HPA) axis, which acts in coordination with circadian rhythm [99].
In a normal situation, a stressor will act on a mammal causing the hypothalamus
to release corticotrophin-releasing hormone (CRH), which activate the neuro-endocrine
cells of the pituitary that express the CRH receptor [101]. The pituitary will release
adrenocorticotropic hormone (ACTH) into the circulatory system, which stimulates the
release of stress hormone, adrenal glucocorticoid hormone, from adrenals. In man, these
adrenal steroid hormones are called cortisol and in rodents, they are referred to as
corticosterone. Adrenal steroid hormones will feedback to the hypothalamus helping to
bring the HPA axis back to homeostasis and preventing excess adrenal steroid hormones
from damaging the body [99].
The HPA axis influences a variety of functions, including glucose release,
immune response, neuroprocessing, such as cognition, long-term potentiation and
emotional response, as well as cardiovascular functions. With such a high impact role,
HPA axis stability is an organism’s most important coping mechanism when
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encountering acute stress. The HPA axis is designed to keep us healthy and adaptable to
novel situations throughout our lifespan [99] in response to “acute” stress. When the HPA
axis is never relieved of duty, responding to chronic stress, the system becomes
unregulated and the normal feedback inhibition fails, which translates into harmful
effects on multiple systems [102].
Adrenal steroid hormone is so powerful across multiple systems because it affects
the neuron in several ways. Adrenal stress hormones bind both mineralocorticoid (MR)
and glucocorticoid (GR) receptors found in the cytosol, affecting gene expression when
the receptors ultimately bind to specific parts of DNA, as well as certain transcription
factors and co-factors. Additionally, adrenal steroid hormones bind MR and GR found in
the membrane (59) contributing to neuronal responses that are unrelated to gene changes
[99].
It stands to reason that the more access the brain has to adrenal steroid hormone,
the more influence this hormone will have on the brain. The hypothalamus has many MR
and GR receptors, while the close proximity of the dentate gyrus to blood vessels [103]
may allow for the increased impact of stress through circulation, as stress hormones are
lipophilic and can pass through the blood brain barrier. This environment could make it
easy for NPC to be affected by high levels of stress hormone.
While MR and GR concentrations play a large role in mediating the stress
response, GR levels have shown to be higher in neuronal precursor cells both in vivo
[104] and in culture [105]. This leads researchers to believe the GR is the main mediator
of stress response in neurogenesis and neuronal progenitor cells, while also affecting
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migration and functional integration of newborn neurons [99]. The role of stress on the
process of neurogenesis led us to focus on eliminating this variable as much as possible.
One factor that was in our favor was that the next part of our study included drug
treatments containing simvastatin. This drug seems to have positive effects on our
systems irrespective of stress. For instance, simvastatin, as an HMG-CoA inhibitor,
lowers lipids and may blunt adrenal hormone production [106]. It has been suggested that
an unborn child can be shielded from the negative effects of maternal stress by treating
the mother with statins [107].
However, our other drug, fluoxetine, is influenced by stress and this will affect
studies that analyze for its impact on neurogenesis. In 2005, Windle and Corbett studied
the recovery of motor abilities after focal ischemia, as a function of neurogenesis, using
fluoxetine in mini pumps [108]. Their rats were half the size of ours, indicating that they
were also much younger. The rodents endured a stroke surgery in addition to a surgery
for placement of the mini pump between the shoulder blades. After 21 days, the mini
pumps had to be changed. Windle and Corbett did not see any neurogenesis in the
subventricular zone (SVZ) [108]. The stress of multiple surgeries precluded them from
seeing the influence of fluoxetine.
Again, stress was shown to negatively influence neurogenesis in the SVZ when
adult rats were treated with fluoxetine via daily intraperitoneal injections over a twoweek period of time. This group only examined neurogenesis in the posterior SVZ, as
they were primarily studying the hippocampus neurogenesis. While neurogenesis in the
SVZ varies, becoming less as you move further posterior, they should have seen at least a
small effect of the fluoxetine in the posterior SVZ (as we did), but they did not [109].
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This is likely because the stress of the manner of delivery fought against the effects of
fluoxetine.
The effect of a stressful drug administration method was tested when glucose
levels in rats were compared. Diogo et al. tested glucose levels of rats that voluntarily
ingested their medication and rats that were subjected to oral gavage [110]. Oral
administration was shown to be highly effective and less stressful on the animal, as well
[110]. We believe that by having the animals ingest their medications orally, the effects
of our drugs were not inhibited by the stress of typical administration methods.
Since we used Doublecortin labeling as our method of identifying migrating
neurons, we can be sure that these new cells are in migration mode, but we cannot
confirm that their fate is that of a neuron. Our results showed that these cells were located
in the subventricular zone, they had divided from either a stem or progenitor cell and they
were in migration process. They had a 19-fold increase in the mean area of staining when
treated with the fluoxetine/statin drug combination versus control. A study combining
this drug combination with more than one marker in the staining process, would allow for
a higher level of cell fate confirmation and provide more robust results for neurogenesis
in the animal model.
In 2006, researchers in China did just that. While neurogenesis in the rodent brain
has been studied for years, research on human neurogenesis is rarer. A group of scientists
in China took biopsies in the peri-infarct region of people suspected of having a stroke.
Their results provided data attesting to similar neurogenesis results in humans, as seen in
rodents. The experiment used Doublecortin for staining, which confirms that
Doublecortin will stain migratory cells in the injured region in humans, as it does in
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rodents. They took the necessary steps to ensure that the data collected were robust. The
team labeled for multiple markers including endogenous-cell-proliferation markers and
neuronal-lineage markers. They confirmed migratory neuroblasts co-located next to
blood vessels. Carmichael’s lab has shown similar results for this co-location of
migratory neuroblasts and blood vessels, as well [111]. Together these data provided
evidence that humans also undergo neurogenesis after stroke [112].

Controllable vs Uncontrollable Stress
There seems to be a physiological difference between controllable and
uncontrollable effects of stress. Here we have focused on the negative impacts of stress
on neurogenesis in the brain. The HPA axis activation promotes neurogenesis showing
that increased stress and adrenal hormones affect the body differently when that stress
can be controlled [99]. Exercise increases stress hormones in the blood [113].
Interestingly, this type of controlled stress will also support neurogenesis at the
proliferation stage and foster differentiation [99], while also facilitating survival of the
newborn neurons within the dentate gyrus of the rat [114]. There is a possibility that the
positive effect on neurogenesis seen with exercise is linked to the increase in eNOS
activity that are seen with increased physical activity as well as social interaction [114].
Learning, enriched environment and sexual experience have shown similar results,
promoting proliferation and integration of new neurons [99] [115].
Researchers identified a difference between acute and chronic sexual experience.
While both increased circulating stress hormone, acute sexual experience increased
proliferation in the dentate gyrus and chronic experience increased both neurogenesis and
proliferation in the dentate gyrus of the adult rat [116]. The opposite is true for
68

uncontrollable stress such as social defeat, fear and chronic stress (vs acute). In this case,
stem/progenitor cell proliferation and integration are both inhibited in response to
increased stress [99]. The fact that uncontrollable stress has a negative impact on
neurogenesis seems to hold true independent of species, age or stressor. Similar reports
are documented with the mouse, rat, tree shrew and marmoset [117]. Studies examining
many uncontrollable stressors, such as resident-intruder, predator odor, isolation and cold
swim, all observed an inhibition of cell proliferation [117].
Although it is clear that the nature of the stressor plays the most important role,
the complexity of the stress system has made it difficult to identify the underlying
mechanisms that differentiate each physiological response [99].
The neurogenesis we observed could be the effect that these drugs, as well as
stress have on growth factors, Brain-Derived Neurotropic Factor (BDNF) and Vascular
Endothelial Growth Factor (VEGF). BDNF is a neurotrophin that plays an important role
in the survival and differentiation of new neurons in the nervous system [118]. This was
verified when SVZ neuroblasts displayed long-term survival after being given BDNF
[119]. Viral overexpression of BDNF in the lateral ventricles nearly doubles the
production of new neurons in the olfactory bulb [120]. BDNF not only helps maintain
neuronal physiological activity [121], but it also enhances synaptic plasticity, enabling
long-term potentiation [122]. BDNF expression is increased with hypoxia and is required
for the proper development and survival BDNF of serotonergic, GABAergic, cholinergic
and dopaminergic neuron development [123] [124].
VEGF is also upregulated in response to hypoxia and stimulates angiogenesis.
VEGF is an angiogenic, and can stimulate neurogenesis both in vitro and in vivo [125].
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In endothelial cells, VEGF can protect and promote cell survival [126], [127]. Neurons
express VEGF receptors similar to endothelium allowing some of the same functions to
be performed across both cell types [125].
Fluoxetine increases the gene expression for BDNF [128] as well as the
expression of VEGF [129], so we hypothesized that without undue stress antagonizing
these effects, these growth factors could induce neurogenesis in our rat model. Both
BDNF and VEGF have been shown to increase in expression in response to simvastatin
in the dentate gyrus, although more caudal than the anterior SVZ, where we were
investigating [130]. It makes sense that treatment with fluoxetine would increase
neurogenesis in our model and that combined with simvastatin, we might see more
enhanced results. We are the first study to show increased neurogenesis in the SVZ in
response to fluoxetine in rats.

Gene Analysis
Within the fluoxetine treatment versus vehicle, the up-regulated genes were
largely involved in channel activity (10 genes, p<0.05). Fluoxetine modifies the
conductance of the voltage-dependent anion channel (VDAC) which is also called a
mitochondrial porin [131]. The modification of conductance ultimately prevents the
release of cytochrome c and protects against apoptosis [131]. Other voltage dependent
channels that fluoxetine has been found to affect include Na+/K+ and Ca+ channels [132]
and [133]. Our gene analysis showed that there changes in channel activity when treated
with fluoxetine versus control.
When we looked at the up-regulated genes associated with the fluoxetine
combination treatment, the effect of statins on clotting activity was very apparent. Statins
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may reduce the effect of stroke by up-regulating eNOS [134]. Endothelial nitric oxide
synthase (eNOS) is an enzyme that serves as a protectant in vascular smooth muscle
[135]. ENOS is anti-thrombotic, anti-inflammatory and reduces smooth muscle
hypertrophy in blood vessels. A lack of eNOS leads to platelet aggregation, increased
smooth muscle proliferation, greater leukocyte adhesion to the endothelium and a rise in
blood pressure [135].
The up-regulation of eNOS not only inhibits clotting activity, but also leads to an
increase in circulating endothelial progenitor cells (EPC) [135]. Together eNOS and
EPCs promote vascular health by boosting angiogenesis, reducing atherosclerosis and
supporting vascular repair [70]. This corresponds to the reduction in the immune
response we saw during our gene analysis when comparing the statin treatment group
against the control group.
Interestingly, we also found a significant effect in the fluoxetine combination
treatment group versus the statin treatment group involving a set of down-regulated genes
associated with the immune response. This could be due to statins down-regulating effect
on the pro-inflammatory chemokine network [136] or the influence of fluoxetine
treatment on the M1 inflammatory type microglia and M2 growth supportive microglia
subtype [137].
The M1 type microglia are necessary during an immune response, as they will
remove debris from the wound, kill tumors and initiate the recruitment of the M2
microglia to assist in new blood vessel growth and the deposition of extracellular matrix.
In order to do their jobs, the M1 microglia must release pro-inflammatory cytokines.
However, during wound sterilization, the surrounding healthy tissue may also be
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damaged [138]. However, with the statin treatment creating anti-inflammatory effects,
the pro-inflammatory cytokine response could be markedly decreased.
Fluoxetine treatment downregulates the expression of the M1 inflammatory type
microglia and upregulates the expression of the M2 supportive microglia subtype [137].
Our gene analysis found a trend towards reduced immune response in our Fluoxetine
combination treatment group and this could be due to the roles that chemokines play
during the microglia activation stages. For instance, while some chemokines are
produced in high concentrations to guide the migration of inflammatory cells to an injury
site, others are involved in anti-inflammatory roles. The down regulating of IL-8
expression, if present in leukocytes, will inhibit inflammation and thrombotic effects,
while activation of macrophages in the presence of IL-4 or IL-13 will promote
angiogenesis and matrix remodeling and suppress destructive immune response through
support of the M2 macrophage [139]. Statins have the ability to promote a Th2 type of
response as one of their many immunomodulatory properties [140]. The Th2 response
consists of increased expression of IL-4, IL-5 and IL-13. The switch from the M1
inflammatory response to the M2 response involving the production of neuroprotective
factors involved in the repair, is induced by the stimulation of anti-inflammatory
cytokines IL-4 and IL-13.
To refine these findings, future experiments could focus on the influence of
fluoxetine and simvastatin on these different chemokines. Additionally, the real time
PCR gene analysis should be performed to assess if the results found in our rat Gene Chip
analysis are reproducible, particularly in regards to the effects of fluoxetine and statins
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ability to change a phenotype of an inflammatory M1 microglia into an M2 growth
supportive microglia.

The Gene Ontology Analysis
Our gene analysis showed the most significant effects in the two fluoxetine
treatment groups, with both of them upregulating gene sets for Forkhead box alpha-1
(Foxa1) and Hypoxia-inducible factor 1-alpha (HIF1a). FoxA1, which is sometimes
referred to as Hepatocyte nuclear factor-3 alpha (HNF-3a) was first identified in the liver
and is characterized by the forkhead binding domain, which is a highly conserved protein
domain specifically shaped for DNA-binding. It is essential for endodermal development
[141]. Additionally dose dependent roles of FoxA1/A2 have been identified during
development to regulate differentiation of dopaminergic neurons in the midbrain [142].
With strong ties to embryogenesis and a consistent role in differentiation, the Fox
gene family was an expected find during our study and analysis. Using fluoxetine in our
experiments could have enhanced the probability of this expression, since fluoxetine
seems to increase neurogenesis and the Fox family is tied to this process. Another
influencing factor in this study could be our inclusion of ascorbic acid, which has been
shown to increase the number of dopaminergic neurons [143], while the Fox family plays
a role in dopaminergic neuron differentiation [142]. This study did not look into every
link, but since fluoxetine has also been shown to increase dopamine in the extracellular
space, the administration of this SSRI could have influenced the gene analysis by
influencing other processes, as well.
Hypoxia-inducible factor 1-alpha (HIF-1-a) is a gene involved in the response to
hypoxia. Fluoxetine has been shown to increase expression of HIF1A protein above that
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of control in stroke model mouse [144]. Angiogenesis and hypoxia have been linked in
studies of ischemic environments [145]. Hypoxia stimulates vascular progenitors that
express endothelial markers like eNOS and growth factors such as vascular endothelial
growth factor, VEGF [145].
As HIF begins to accumulate, the transcription of growth factors, BDNF and
VEGF increases and the up-regulation of vascular progenitors will occur near the
ischemic site. VEGF promotes angiogenesis through phosphorylation of Akt, which
activates the pathway that increases eNOS levels [145]. Although we did not target
angiogenesis as the focus of the experiment, vascularization is necessary for neurogenesis
to be significant and survive long-term. Thus, our results suggest vascularization took
place at some level. Future studies testing our drug combination with an assay for
endothelial cell migration for VEGF would be beneficial to confirm this suggestion. We
know that both simvastatin and fluoxetine increase BDNF and VEGF: it is possible that
targeted increases in HIF1A that produce these changes. We did not see any evidence of
infarcts in these animal models, either functionally or in the dissected brain, so the
HIF1A would not have been produced by ischemia per se in our experiments. More
research is necessary to understand the direct effect of these drugs on Hypoxia Inducible
Factor 1A.
When we examined the results of the simvastatin/ascorbic acid treatment group
versus vehicle we found that the differentially expressed genes up-regulated with a >2
fold change (p<0.05) belonged to mostly to the ontology of biological processes. Most
importantly, the biological processes are involved in transport, regulation and response,
Table 22. Within this same comparison, the simvastatin/ascorbic acid treatment group
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versus vehicle, we identified the differentially expressed genes, Alpha-2-macroglobin
(A2m), Protein kinase c-delta (Prkcd), Sclerostin domain containing-1 (Sostdc1), which
are common to a variety of signaling pathways, Table 23.
The gene named Alpha 2 Macroglobulin (A2M) showed in our genetic ontology
report as a significant contributor to our results. It encodes for a protein that binds brainderived neurotropic factor (BDNF) and is considered an acute-phase protein available
when the body encounters challenges such as cardiac infarctions [146]. Scientists have
found a role for A2M in the coagulation cascade pathway in rats [147]. Although our
method of inducing coagulation of the MCA was not successful, the action itself could
have had implications that influenced this gene activation and its presence in our gene
analysis.
Protein kinase c-delta (Prkcd) belongs to a family activated by calcium and
diacylglycerol. The family can phosphorylate multiple protein targets making it
responsible for a wide array of cellular signaling pathways. This particular gene plays a
role in growth and apoptosis regulation, in addition to differentiation of an assortment of
cell types [148]. Protein kinase c has been shown to be a mediator of reperfusion injury in
different organs [149]. A peptide inhibitor selective for PKC reduced cellular injury in rat
hippocampus slices. The same researchers used an in vivo rat stroke model, occluding the
MCA, where the infarct size was decreased when the peptide inhibitor was used. There
was no effect when this inhibitor was delivered before injury. Decreased infarct size was
only seen when the PKC inhibitor was delivered at onset, 1 hour and 6 hours of
reperfusion [148]. The same researchers went on to find that PKC also decreased
apoptosis and increased the levels of phosphorylated Akt [148]. As previously
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mentioned, the hypoxic response increases phosphorylated Akt, which in turn increases
eNOS and is involved in cell survival pathways. Future research could be done to discern
the specific roles of the PKC gene and investigate techniques to regulate the expression.
These results could possibly provide leverage for the advancement in the genetic
treatment of stroke [148].
The Sclerostin domain containing-1 gene, encodes for the protein also known as
Wise. Wise indirectly affects proliferation, differentiation and apoptosis by associating
with bone morphogenetic protein (BMP). Through association, Wise prevents BMP from
binding to receptors [150]. Wise is a Wnt modulator and will reduce BMP signaling in
fibroblasts. Scientists believe that Wnt pathway is active and acts on the hippocampus
throughout the lifespan [151]. Long-term potentiation is the result of Wnt ligand acting
locally to shape the pre and post synaptic connections [150].
While our gene results were interesting and provided a good baseline for future
studies, we cannot be sure that we would get the same results if we had analyzed tissue
from the subventricular zone. The lab has continued studies with in gene expression in
the peri-infarct area after endothelin-induced stroke and has shown through real time
PCR that our drugs decrease the inflammatory response of the immune system and
increase growth factors, leading to a smaller infarct size [152] (work involving
Dissertation research by Moner Ragas, and thesis work of Dr. Neal Verma.)

Biology and Statistics
Statistics play a large role in scientific research. Interpreting causality and
probability under specific conditions, paves our way to understanding how we can
improve the lives of humans, animals and the planet. Biology is a unique discipline.
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Understanding biology means grasping the concepts of mechanisms, how they overlap to
influence one another and the influence of behavior, environment and chemicals on these
mechanisms. Biology is not always predictable and the randomness of the science is the
beauty. What we do know is that we can influence biology, as stated before, through
behavior, environment and chemicals. That is what we are trying to do when we set up
biological experiments. However, when we use statistics to describe our results, it should
be with the knowledge that biology is not a static system. At the macroscopic level,
biology can be described with methodical language, laws of physics and hard statistics.
But, the smaller we go, the more molecular we get, and embedded we become in the
mechanisms of a living system that will never behave the same as a nonliving object.
This research shows great significance in the mean area of Doublecortin staining
while using our drug combination treatment. We took measures to remove stress from the
administration method to keep that variable out of our results. In one statistical
measurement we saw that when we analyzed the area using a smaller unit, micrometers
squared, we gained significance within the fluoxetine treatment group that was not there
when we analyzed in millimeters squared. When we changed from millimeters squared to
micrometers squared, we increased the numerical range, which made it easier to identify
a statistical significance. When performing statistics on a living animal, there will be a lot
of variability from animal to animal. The genetic variability will influence how the drugs
work on them, but the ultimate test is to have this research on a living animal before
moving on to clinical trials. When we examined Doublecortin staining in millimeters
squared, we saw a 19-fold increase in the mean area of Doublecortin staining with the
fluoxetine combination group, which was significant and an 11-fold increase in the
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fluoxetine treatment group, which was not significant. Although, not statistically
significant in millimeters squared, an 11-fold increase in neurogenesis would likely have
biologically significant effects on a living creature. We saw this difference in significance
simply because the sensitivity of our statistical tests increased with the greater numerical
range.
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Conclusion
One of the largest issues in conducting experiments with live animals is the risk of
stress interfering with the results. The first part of this study brought great results as we
identified a medium for the voluntary oral administration of medication using plain sugar
cookie dough. The method was tested in two different strains of rats (Fisher and Wistar),
in addition to both genders in the Fisher strain and found to be reliable 99.48-100% of the
time. We now have a method of medication administration that eliminates the
unnecessary stress and extreme weight loss that can be seen when using IP injections or
oral gavage.
We looked at three different drug treatments and their effect on neurogenesis.
Fluoxetine (5mg/kg), simvastatin (0.5 mg/kg) plus ascorbic acid (20 mg/kg) and a
combination treatment of fluoxetine, simvastatin and ascorbic acid (5mg/kg, 0.5mg/kg,
20mg/kg, respectively) were tested against control (no treatment). We found that the
combination of fluoxetine and statin with ascorbic acid produced the most effective and
significant results. The efficacy is demonstrated through increased area of Doublecortin
staining in the anterior lateral ventricles of the SVZ. The staining identified neurons
expressing the Doublecortin protein, which is found in neuroblasts and when compared
with control, the fluoxetine combination treatment showed a 19-fold increase in mean
area of neurogenesis.
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Neurologists can utilize these results as a step towards increasing neurogenesis for
improvement in multiple disorders, such as Alzheimer’s, stroke, Parkinson’s,
depression,addiction and PTSD. Additionally, by drawing the parallel between the
dynamic instability of microtubules and their role in neurogenesis, computer scientists
can study the mechanisms and hypothesize concepts for autonomous systems that react to
external stimuli by reconfiguring the circuit [153].
Since not all mechanisms of neurogenesis are understood and we do not hold a
firm understanding of how to manipulate or control neurogenesis, it is necessary that we
track and study the genetic component that is integrated within the process. To add
another layer of information to the study, we had a gene chip analysis performed on
cortical tissue that received the different drug treatments. We think it is critical to the
future management of neurogenesis to understand which genes are involved and to what
extent. If we identify which genes are regulating neurogenesis we can look into possible
modes of manipulation. The gene study that we performed added useful information but
we were not able to confirm the results we were seeing at that time with real time PCR.
For the study to supply pertinent results for future applications, we would have needed to
use samples near the subventricular zone. Additionally, we will need to be meticulous in
our processes and not to assume direct correlations between gene expression and protein
expression. Many things can affect gene expression. At times, an upregulation of gene
expression does not cause a protein to be expressed. It is not uncommon to have false
positives in gene chips with the dynamics in such a nonlinear system. In order to get a
broader idea of what was going on, we used the less rigorous method of gene expression:
gene chip. We would need to go back and retest these results with real time PCR if we
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wanted to validate these findings. Once we have labeled and performed a gene chip study
using the specific area, the next steps are to confirm protein expression with IHC and
Western blot and confirm gene chip expression with real-time PCR. We did not get to
confirm our gene chip with PCR methods so there could have been false positives in
these early results. We cannot rely on the gene chip analysis alone.
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Future Studies
Noting that there is a physiological difference between controlled and
uncontrolled stress, these conditions should be compared utilizing the fluoxetine
combination treatment. Given that controlled stress has the ability to facilitate survival of
newborn neurons, our results with the drug combination could possibly be enhanced or
even strengthened. Since learning, enriched environment and sexual experience have also
been shown to increase neurogenesis, any of these avenues should be explored in
conjunction with the drug treatment, as well.
We did not see an increase in BDNF or VEGF in our gene results. These growth
factors are highly localized around the infarct region and the Doublecortin expression
region because Doublecortin is attracted to BDNF. By using cortex rather than SVZ
samples for the gene expression studies, we decreased the possibility that we would see
these growth factors, particularly since we did not induce an infarct with our stroke
surgery. Later studies from this laboratory have focused on the peri-infarct region for the
gene expression analysis, and have shown increase in a number of growth factors,
including BDNF. If we can use our drug combination to increase neurogenesis and both
of these growth factors that facilitate the process, we can begin to look at novel
approaches to treatment of stroke, as well as gene therapy.
Next time, we should not look solely at cells that label with Doublecortin, but also
look at cells that label with neuronal nuclear protein (NeuN). NeuN, although exclusively

82

found in nervous tissue, it is not found in immature neural progenitor cells, nor is it
detected in glial cells [154]. This suggests that it is specific for marking the neuronal
phenotype. A benefit is that NeuN expression is associated with the nucleus instead of the
cytoplasm, which allows the cells to be more discretely stained and therefore makes it
easier for later binary image processing [154].
NeuN is a product of Fox-3, which is also expressed only in nervous tissue and
has the exact same Immunocytochemistry staining pattern as NeuN [154]. Fox-3 belongs
to the Fox-1 family [154] and we saw a change in the Fox gene in our genetic analysis.
Performing a neurogenesis study to test our drug combination using Western blot in
combination with IHC could provide the powerful results we need to revisit our gene
analysis on Fox1.
Lastly, it has been found that physical activity increases the proliferation of
microglia and that ageing is associated with increased microglia activation towards the
M1 inflammatory phenotype. Studies performed using physical activity and the
fluoxetine/statin drug combination could prove to support the M2 response, as a way to
clear debris and necrotic tissues while promoting neurogenesis [139]. This same approach
could be used as a treatment program with ageing individuals as a preventative measure.
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Appendix
Up‐regulated and Down‐regulated Genes
IGG2A_RAT
Ttr
Kcnj13
LOC100363671
Sostdc1
Clic6
Cldn2
Cxcl13
Prkcd
Cacna1i

fold‐Simv+Ascorb_vs_Vehicle
fold‐Fluoxetine_vs_Vehicle
fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb
3.640024935
‐1.100687302
‐1.217169426
‐4.43052706
3.347527715
‐1.248152315
5.104085513
1.524732862
3.133986938
1.140047683
2.105326761
‐1.488598823
3.09393953
1.123327812
‐1.038105691
‐3.211836232
2.865361175
‐1.037633527
2.379233171
‐1.204321295
2.647506574
‐1.042854679
1.931338442
‐1.370814414
2.581984488
‐1.03055226
1.640486059
‐1.573914313
2.421881594
‐1.158783194
1.137900964
‐2.128376432
2.323790449
1.613633765
1.522909043
‐1.525889193
2.250675918
2.48733415
2.721100045
1.2090146

LOC100361322
F1M6L0_RAT
RGD1560095
D3ZUT2_RAT
D3ZZI9_RAT
Gucy2f
RGD1565410
F1M1X1_RAT
F1M4J8_RAT
F1M9E2_RAT

fold‐Simv+Ascorb_vs_Vehicle
fold‐Fluoxetine_vs_Vehicle
fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb
‐2.944293175
‐2.419071369
‐3.143416266
‐1.067630185
‐2.372844677
‐1.517038466
‐1.955033506
1.213710491
‐2.355208854
‐1.536143508
‐2.146619765
1.097170953
‐2.322559141
‐1.631958458
‐1.713926212
1.355110345
‐2.289411293
‐1.33040608
‐1.816983099
1.260006928
‐2.286089681
‐1.21093716
1.082469718
2.474622853
‐2.229691326
‐1.356263972
‐2.244537708
‐1.006658492
‐2.223150062
‐1.687300968
‐1.054306984
2.10863638
‐2.162771624
‐1.754740062
‐1.845331489
1.172023367
‐2.162609975
‐1.58926918
‐2.073836992
1.042806153

Lrrc7
Cacna1i
D3ZCX4_RAT
U2
U2
F1M4F6_RAT
U6
rno‐mir‐384
Slc12a6
rno‐mir‐380

fold‐Fluoxetine_vs_Vehicle
fold‐Simv+Ascorb_vs_Vehicle
fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb
2.619065245
1.967819644
2.228693668
1.132570088
2.48733415
2.250675918
2.721100045
1.2090146
2.294937716
1.31545783
1.593197366
1.211135264
2.244341686
1.498790079
2.059896237
1.374372746
2.244341686
1.498790079
2.059896237
1.374372746
2.189673348
1.517145726
1.943681277
1.281143429
2.162407369
1.527408898
2.271788193
1.487347753
2.161533706
1.439282045
1.792456781
1.245382576
2.111941686
2.216010934
1.681517935
‐1.317863395
2.05746706
1.47775114
1.709222247
1.156637407

F1M4A3_RAT
LOC100361322
LOC100360329
Fam71e2
D4A684_RAT
F1M509_RAT
F1LYV9_RAT
D4ABQ4_RAT
LOC100364560
Mup4

fold‐Fluoxetine_vs_Vehicle
fold‐Simv+Ascorb_vs_Vehicle
fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb
‐3.115556759
‐1.474291699
‐1.159493715
1.271496067
‐2.419071369
‐2.944293175
‐3.143416266
‐1.067630185
‐2.180870845
‐1.139174165
‐2.302729582
‐2.021402567
‐2.088526332
‐1.380490857
‐1.29713173
1.064264195
‐2.07231742
‐1.595934011
‐1.408103454
1.133392583
‐2.033976015
‐1.82305826
‐2.455190553
‐1.346742782
‐1.994479553
‐1.807059905
‐1.798947811
1.004509355
‐1.969484869
‐1.217934319
‐1.121470496
1.086015479
‐1.953579545
‐1.114117968
‐1.933002272
‐1.735006819
‐1.948709897
‐2.044725721
‐2.31145162
‐1.130445808

Ttr
Cacna1i
Sostdc1
U6
Lrrc7
Kcnj13
U2
U2
D3ZX37_RAT
Mug1

fold‐Sim+Asc+Flu_vs_Vehicle
fold‐Sim+Asc+Flu_vs_Simv+Ascorb fold‐Simv+Ascorb_vs_Vehicle fold‐Fluoxetine_vs_Vehicle
5.104085513
1.524732862
3.347527715
‐1.248152315
2.721100045
1.2090146
2.250675918
2.48733415
2.379233171
‐1.204321295
2.865361175
‐1.037633527
2.271788193
1.487347753
1.527408898
2.162407369
2.228693668
1.132570088
1.967819644
2.619065245
2.105326761
‐1.488598823
3.133986938
1.140047683
2.059896237
1.374372746
1.498790079
2.244341686
2.059896237
1.374372746
1.498790079
2.244341686
2.049844777
1.005603702
2.038422066
1.585700822
2.03181634
1.51658252
1.339733455
1.430760307
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LOC100361322
D3ZPQ1_RAT
LOC100364370
F1M509_RAT
Ly49i3
Dpt
Mup4
LOC100360329
RGD1564848
RGD1565410

fold‐Sim+Asc+Flu_vs_Vehicle
fold‐Sim+Asc+Flu_vs_Simv+Ascorb fold‐Simv+Ascorb_vs_Vehicle fold‐Fluoxetine_vs_Vehicle
‐3.143416266
‐1.067630185
‐2.944293175
‐2.419071369
‐2.654006063
‐1.359310147
‐1.952465424
‐1.411529226
‐2.539782581
‐1.324562574
‐1.917450056
‐1.774808048
‐2.455190553
‐1.346742782
‐1.82305826
‐2.033976015
‐2.354999358
‐1.36566882
‐1.724429323
‐1.36119806
‐2.313763915
‐1.133615194
‐2.041048786
‐1.764883148
‐2.31145162
‐1.130445808
‐2.044725721
‐1.948709897
‐2.302729582
‐2.021402567
‐1.139174165
‐2.180870845
‐2.265019284
‐1.208845424
‐1.873704644
‐1.6165882
‐2.244537708
‐1.006658492
‐2.229691326
‐1.356263972

Gucy2f
F1M1X1_RAT
Abhd15
Myo7b
rno‐mir‐142
D3ZQ54_RAT
LOC683745
D3ZH73_RAT
D4A8P2_RAT
F1LVU9_RAT

fold‐Sim+Asc+Flu_vs_Simv+Ascorb fold‐Simv+Ascorb_vs_Vehicle
fold‐Fluoxetine_vs_Vehicle
fold‐Sim+Asc+Flu_vs_Vehicle
2.474622853
‐2.286089681
‐1.21093716
1.082469718
2.10863638
‐2.223150062
‐1.687300968
‐1.054306984
2.043063436
‐1.720089937
‐1.412971141
1.187765472
1.922828377
‐1.24287396
‐1.024242977
1.547082358
1.897696132
‐1.262232201
1.186115636
1.503444558
1.848531549
‐1.318370927
1.387578764
1.402133126
1.84192204
‐1.576999278
‐1.409899179
1.167991682
1.786042404
‐1.485454759
1.139587209
1.202353955
1.755856569
1.017082471
1.237416063
1.785850939
1.735562116
‐1.321855675
‐1.375963945
1.312973987

IGG2A_RAT
LOC100363671
RT1‐Da
F1LV34_RAT
IGG2B_RAT
F1LPR6_RAT
Cxcl13
Gpr88
Cd74
F1LNR3_RAT

fold‐Sim+Asc+Flu_vs_Simv+Ascorb fold‐Simv+Ascorb_vs_Vehicle
fold‐Fluoxetine_vs_Vehicle
fold‐Sim+Asc+Flu_vs_Vehicle
‐4.43052706
3.640024935
‐1.100687302
‐1.217169426
‐3.211836232
3.09393953
1.123327812
‐1.038105691
‐2.396851288
1.952817416
‐1.166894825
‐1.227381151
‐2.371643231
1.321883773
‐1.256712523
‐1.794139
‐2.33821431
1.668500555
‐1.069501743
‐1.401386594
‐2.158869444
1.727875576
1.066447787
‐1.249435708
‐2.128376432
2.421881594
‐1.158783194
1.137900964
‐2.108574019
1.362403771
1.020890642
‐1.54768657
‐2.074565749
1.969342964
1.081091311
‐1.053430401
‐2.061841834
1.734630843
‐1.080300994
‐1.188634368
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Gene Profiler
Up-regulated in Fluoxetine vs Control
term
type

Term Query
Common Genes
Genes Genes
#
#

p-value

T

Q

Q&T

Q&T/Q

Q&T/T

term ID

t type

term
group
term name and depth in
t group group

1 1.65E-02

2

57

2

0.035

1 GO:0035068

CC

1 2.96E-02

389

57

8

0.14

0.021 GO:0022803

MF

micro-ribonucleoprotein
4 complex
passive transmembrane
3 transporter activity

1 2.96E-02

389

57

8

0.14

0.021 GO:0015267

MF

3

1 3.43E-02

285

57

7

0.123

0.025 GO:0022836

MF

3

1 2.14E-02

174

57

6

0.105

0.034 GO:0022832

MF

1 2.02E-02

369

57

8

0.14

0.022 GO:0022838

MF

gated channel activity
voltage-gated channel
3 activity
substrate-specific
3 channel activity

1 1.66E-02

359

57

8

0.14

0.022 GO:0005216

MF

3

1 3.43E-02

285

57

7

0.123

0.025 GO:0022839

MF

3

1 2.14E-02

174

57

6

0.105

0.034 GO:0005244

MF

ion gated channel activity
voltage-gated ion
3 channel activity

1 2.48E-02

271

57

7

0.123

0.026 GO:0005261

MF

3

1 3.81E-03

129

57

6

0.105

0.047 GO:0022843

MF

1 1.83E-04

4

57

3

0.053

0.75 GO:0008332

MF

1 2.75E-03
1 8.46E-03

182
46

56
56

5
3

0.089
0.054

0.027 KEGG:04020
0.065 KEGG:04930

ke
ke

Down in S+A vs V

(none)

Down in S+A+F vs V

(none)

Up in S+A+F vs S+A

(none)
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channel activity

ion channel activity

cation channel activity
voltage-gated cation
3 channel activity
low voltage-gated
5 calcium channel activity
Calcium signaling
1 pathway
2 Type II diabetes mellitus

Q&T list

1 TNRC6A,EIF2C3
CACNA1I,GABRG3,KCNH5,SCN4B,SL
1 C24A2,CACNA1G,KCNH7,CACNA1E
CACNA1I,GABRG3,KCNH5,SCN4B,SL
2 C24A2,CACNA1G,KCNH7,CACNA1E
CACNA1I,GABRG3,KCNH5,SCN4B,CA
3 CNA1G,KCNH7,CACNA1E
CACNA1I,KCNH5,SCN4B,CACNA1G,K
4 CNH7,CACNA1E
CACNA1I,GABRG3,KCNH5,SCN4B,SL
1 C24A2,CACNA1G,KCNH7,CACNA1E
CACNA1I,GABRG3,KCNH5,SCN4B,SL
1 C24A2,CACNA1G,KCNH7,CACNA1E
CACNA1I,GABRG3,KCNH5,SCN4B,CA
1 CNA1G,KCNH7,CACNA1E
CACNA1I,KCNH5,SCN4B,CACNA1G,K
2 CNH7,CACNA1E
CACNA1I,KCNH5,SCN4B,SLC24A2,CA
1 CNA1G,KCNH7,CACNA1E
CACNA1I,KCNH5,SCN4B,CACNA1G,K
2 CNH7,CACNA1E
1 CACNA1I,CACNA1G,CACNA1E
CACNA1I,EGFR,PLCB4,CACNA1G,CA
1 CNA1E
1 PRKCD,CACNA1G,CACNA1E

Up in S+A vs V

#
#

p-value

T

Q

Q&T

Q&T/Q

Q&T/T

term ID

t type

t name and depth in
t group group

Q&T list
CXCL13,PRKCD,A2M,CD74,ACE,SLITR
K6,PAX6,SERPING1,FCER1G,SULT2A1,
F1M784_RAT,PLCB4,PENK,ITGAM,NF
ASC,EGFR,LEF1,CXCL16,DRD2
PAX6,NRG1,ITGAM,EGFR,LEF1,GFAP,
1
C1S

1

1.66E-02 1199

101

19

0.188

0.016

GO:0009605

BP

11

response to external
stimulus

1

2.51E-02

152

101

7

0.069

0.046

GO:0010001

BP

7

glial cell differentiation

1

1.22E-02

24

101

4

0.04

0.167

GO:0002504

BP

1

antigen processing and
presentation of peptide or
polysaccharide antigen via
MHC class II

1

CD74,RT1-DA,FCER1G,RT1-BB

1

5.00E-02

2

101

2

0.02

1

GO:0001868

BP

6

regulation of complement
activation, lectin pathway

1

A2M,SERPING1

6

negative regulation of
complement activation,
lectin pathway

2

1

5.00E-02

2

101

2

0.02

1

GO:0001869

BP

1

1

9.01E-03

388

101

11

0.109

0.028

GO:0002252

BP

9

1

1.24E-03

193

101

9

0.089

0.047

GO:0002443

BP

9

immune effector process 1

1

1.95E-03

150

101

8

0.079

0.053

GO:0002449

BP

9

1

3.41E-02 1147

101

18

0.178

0.016

GO:0048584

BP

9

positive regulation of
response to stimulus

1

1

1.86E-03

738

101

16

0.158

0.022

GO:0006955

BP

9

immune response

1

1

6.25E-04

178

101

9

0.089

0.051

GO:0002250

BP

9

1

3.28E-04

165

101

9

0.089

0.055

GO:0002460

BP

9

1

6.43E-04

88

101

7

0.069

0.08

GO:0019724

BP

9

1

5.94E-04

87

101

7

0.069

0.08

GO:0016064

BP

9

1

3.41E-02

447

101

11

0.109

0.025

GO:0002684

BP

9

1

2.25E-02

275

101

9

0.089

0.033

GO:0050778

BP

9

1

5.03E-03

43

101

5

0.05

0.116

GO:0072376

BP

15

leukocyte mediated
immunity
lymphocyte mediated
immunity

2
3

adaptive immune
2
response
adaptive immune
response based on somatic
recombination of immune
3
receptors built from
immunoglobulin superfamily
domains
B cell mediated
4
immunity
immunoglobulin
5
mediated immune response
positive regulation of
immune system process
positive regulation of
immune response
protein activation
cascade

1

101

29

0.287

0.012

GO:0006950

BP

10

response to stress

1

1

3.84E-05

804

101

19

0.188

0.024

GO:0006952

BP

10

defense response

2

1

2.29E-03

750

101

16

0.158

0.021

GO:0009611

BP

10

response to wounding

2

1

3.19E-03 1401

101

22

0.218

0.016

GO:0044459

CC

13

plasma membrane part

1

1

4.99E-02

1

30

1

0.033

1

CORUM:3277

co

12

1

4.99E-02

1

30

1

0.033

1

CORUM:2277

co

4

1

1.44E-03

11

97

4

0.041

0.364

HP:0002725

hp

2

1

6.97E-03

67

101

5

0.05

0.075

KEGG:04610

ke

3

1

4.64E-02

152

101

6

0.059

0.039

KEGG:04514

ke

14

1

1.19E-04

53

101

6

0.059

0.113

KEGG:05150

ke

8

1

2.33E-02

645

101

12

0.119

0.019

MI:hsa-miR-892a

mi

16

1

4.25E-02

50

101

5

0.05

0.1

REAC:440458

re

5

1

1.59E-02

41

101

5

0.05

0.122

REAC:440457

re

5

1

7.23E-03

17

101

4

0.04

0.235

REAC:428237

re

5
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TCR signaling
Downstream TCR
signaling
Change of PKC theta
conformation

PRKCD,CD74,SERPING1,FCER1G,C4B,
C1S,RT1-BB
PRKCD,CD74,SERPING1,FCER1G,C4B,
C1S,RT1-BB

CXCL13,A2M,CD74,SERPING1,FCER1G
,C4B,F1M784_RAT,CD4,RSAD2,C1S,RT
1-BB
A2M,CD74,SERPING1,FCER1G,C4B,F1
2
M784_RAT,RSAD2,C1S,RT1-BB

1.15E-02 2416

MI:hsa-miR-892a

PRKCD,CD74,SERPING1,FCER1G,C4B,
LEF1,RSAD2,C1S,RT1-BB

1

1

D2 receptor-Nsf-GluR2
complex
D2 receptor-GluR2GluR1 complex
Systemic lupus
erythematosus
Complement and
coagulation cascades
Cell adhesion molecules
(CAMs)
Staphylococcus aureus
infection

A2M,SERPING1
PRKCD,A2M,CD74,ACE,SERPING1,FC
ER1G,C4B,LEF1,RSAD2,C1S,RT1-BB
PRKCD,CD74,ACE,SERPING1,FCER1G,
C4B,RSAD2,C1S,RT1-BB
PRKCD,CD74,SERPING1,FCER1G,C4B,
RSAD2,C1S,RT1-BB
CXCL13,PRKCD,A2M,CD74,SHOX2,AC
E,SERPING1,FCER1G,C4B,KL,F1M784_
RAT,NRG1,CD4,EGFR,RSAD2,C1S,RT1BB,DRD2
CXCL13,PRKCD,A2M,CD74,RT1DA,SERPING1,FCER1G,C4B,F1M784_R
AT,FCGR3A,CD4,LEF1,RSAD2,C1S,CX
CL16,RT1-BB
PRKCD,CD74,SERPING1,FCER1G,C4B,
LEF1,RSAD2,C1S,RT1-BB

A2M,F5,SERPING1,C4B,C1S
CXCL13,PRKCD,PALB2,SLC12A6,A2M,
CD74,LRRC7,ACE,F5,PAX6,KRT8,PLA
C8,SERPING1,FCER1G,C4B,KL,OLR1,F
ZD6,F1M784_RAT,FCGR3A,PENK,CD4,
EGFR,GFAP,RSAD2,C1S,CXCL16,RT1BB,DRD2
CXCL13,PRKCD,A2M,CD74,ACE,PLAC
8,SERPING1,FCER1G,C4B,KL,OLR1,F1
M784_RAT,PENK,CD4,EGFR,RSAD2,C1
S,CXCL16,RT1-BB
PRKCD,A2M,ACE,F5,PAX6,SERPING1,
FCER1G,C4B,KL,OLR1,FZD6,F1M784_R
AT,FCGR3A,EGFR,GFAP,DRD2
CACNA1I,SLC12A6,CD74,RT1DA,ACE,TRPM6,KRT8,SCN7A,ACVR1
C,SLC4A5,FCER1G,FOLR1,FZD6,FCGR3
A,NRG1,MYO1D,GNAL,CD4,ITGAM,EG
FR,RT1-BB,DRD2

1

DRD2

1

DRD2

1

SERPING1,C4B,ITGAM,C1S

1

A2M,F5,SERPING1,C4B,C1S

CLDN2,RT1DA,CD4,ITGAM,NFASC,RT1-BB
RT1-DA,C4B,FCGR3A,ITGAM,C1S,RT11
BB
SLC12A7,A2M,ACE,TMEM72,LY49SI1,
1 KL,MYO1D,CD4,LEF1,FCRLS,CYP2J10,
C1S
1
PRKCD,RT1-DA,UBC,CD4,RT1-BB
1

2

PRKCD,RT1-DA,UBC,CD4,RT1-BB

3

PRKCD,RT1-DA,CD4,RT1-BB

Up in S+A+F vs V

#
#

p-value

T

Q

Q&T/Q

Q&T

Q&T/T

term ID

t type

1 1.53E-02

2

51

2

0.039

1 GO:0060838

BP

1 1.53E-02

2

51

2

0.039

1 GO:0060849

BP

1 3.15E-02

29

50

3

0.06

0.103 REAC:440430

re

1 3.32E-02

5

50

2

0.04

0.4 REAC:434580

re

1 1.00E-02

3

50

2

0.04

0.667 REAC:431218

re

88

t name and depth in
t group group
lymphatic endothelial cell
3 fate commitment
regulation of transcription
involved in lymphatic
endothelial cell fate
3 commitment
Formation of Fibrin Clot
4 (Clotting Cascade)
kallikrein + alpha2macroglobulin ->
kallikrein:alpha21 macrogloulin
Exocytosis of alpha 2
2 macroglobulin

Q&T list

1 NR2F2,PROX1

1 NR2F2,PROX1
1 MUG1,A2M,F5

1 MUG1,A2M
1 MUG1,A2M

Down in S+A+F vs S+A

#
#

p-value

T

Q

Q&T/Q

Q&T

Q&T/T

term ID

t type

t name and depth in
t group group

1 2.84E-02

804

49

10

0.204

0.012 GO:0006952

BP

9

defense response

1 8.79E-05

1376

49

16

0.327

0.012 GO:0002376

BP

2

immune system process

1 1.34E-02

198

49

6

0.122

0.03 GO:0070661

BP

2

1 1.06E-02

190

49

6

0.122

0.032 GO:0032943

BP

2

leukocyte proliferation
mononuclear cell
proliferation

1 1.88E-04

738

49

12

0.245

0.016 GO:0006955

BP

2

immune response

1 1.73E-02

595

49

9

0.184

0.015 GO:0001775

BP

2

cell activation

1 5.13E-03

512

49

9

0.184

0.018 GO:0045321

BP

2

leukocyte activation

1 1.10E-03

425

49

9

0.184

0.021 GO:0046649

BP

2

lymphocyte activation

1 8.10E-04

296

49

8

0.163

0.027 GO:0042110

BP

2

1 1.03E-02

189

49

6

0.122

0.032 GO:0046651

BP

2

1 1.49E-03

321

49

8

0.163

0.025 GO:0050865

BP

2

1 1.13E-02

192

49

6

0.122

0.031 GO:0050867

BP

2

T cell activation
lymphocyte
proliferation
regulation of cell
activation
positive regulation of cell
activation

1 1.34E-03

721

49

11

0.224

0.015 GO:0002682

BP

2

1 1.16E-02

298

49

7

0.143

0.023 GO:0002694

BP

2

1 4.04E-03

254

49

7

0.143

0.028 GO:0051249

BP

2

1 4.00E-04

180

49

7

0.143

0.039 GO:0050863

BP

2

1 1.68E-03

447

49

9

0.184

0.02 GO:0002684

BP

2

1 8.54E-03

183

49

6

0.122

0.033 GO:0002696

BP

2

1 4.53E-03

164

49

6

0.122

0.037 GO:0051251

BP

2

1 5.94E-04
1 4.06E-02

116
23

49
49

6
3

0.122
0.061

0.052 GO:0050870
0.13 GO:0001964

BP
BP

2
1

regulation of immune
system process
regulation of leukocyte
activation
regulation of
lymphocyte activation
regulation of T cell
activation
positive regulation of
immune system process
positive regulation of
leukocyte activation
positive regulation of
lymphocyte activation
positive regulation of T
cell activation
startle response

1 1.81E-02

598

49

9

0.184

0.015 GO:0007610

BP

5

behavior

1 2.78E-02

1401

49

13

0.265

0.009 GO:0044459

CC

12

1 4.99E-02

1

14

1

0.071

1 CORUM:2277

co

7

1 4.99E-02

1

14

1

0.071

1 CORUM:3277

co

10

1 6.52E-03

78

49

4

0.082

0.051 KEGG:04612

ke

6

1 1.42E-03

53

49

4

0.082

0.075 KEGG:05150

ke

11

1 7.06E-03

152

49

5

0.102

0.033 KEGG:04514

ke

8

1 1.19E-02

170

49

5

0.102

0.029 KEGG:04145

ke

4

1 4.98E-02

3

49

2

0.041

0.667 REAC:432379

re

3
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plasma membrane part
D2 receptor-GluR2GluR1 complex
D2 receptor-Nsf-GluR2
complex
Antigen processing and
presentation
Staphylococcus aureus
infection
Cell adhesion molecules
(CAMs)
Phagosome
Formation of the
IGF:IGFBP-2 Complex

Q&T list
PRKCD,SERPING1,CD4,PLAC8,C4B,OL
1 R1,PENK,ADORA2A,CD74,CXCL13
MEIS2,CTSC,PRKCD,IGFBP2,SERPING
1,CD4,RT1A2,ITGAL,IGF2,C4B,FCGR3A,IL2RG,AD
1 ORA2A,CD74,CXCL13,RT1-DA
PRKCD,IGFBP2,ITGAL,IGF2,FCGR3A,C
1 D74
PRKCD,IGFBP2,ITGAL,IGF2,FCGR3A,C
2 D74
CTSC,PRKCD,SERPING1,CD4,RT1A2,ITGAL,C4B,FCGR3A,IL2RG,CD74,C
1 XCL13,RT1-DA
PRKCD,IGFBP2,CD4,ITGAL,IGF2,FCGR
1 3A,IL2RG,ADORA2A,CD74
PRKCD,IGFBP2,CD4,ITGAL,IGF2,FCGR
2 3A,IL2RG,ADORA2A,CD74
PRKCD,IGFBP2,CD4,ITGAL,IGF2,FCGR
3 3A,IL2RG,ADORA2A,CD74
IGFBP2,CD4,ITGAL,IGF2,FCGR3A,IL2R
4 G,ADORA2A,CD74
PRKCD,IGFBP2,ITGAL,IGF2,FCGR3A,C
4 D74
PRKCD,IGFBP2,CD4,ITGAL,IGF2,IL2R
2 G,ADORA2A,CD74
2 IGFBP2,CD4,ITGAL,IGF2,IL2RG,CD74
MEIS2,IGFBP2,SERPING1,CD4,ITGAL,I
GF2,C4B,IL2RG,ADORA2A,CD74,CXCL
1 13
IGFBP2,CD4,ITGAL,IGF2,IL2RG,ADOR
2 A2A,CD74
IGFBP2,CD4,ITGAL,IGF2,IL2RG,ADOR
3 A2A,CD74
IGFBP2,CD4,ITGAL,IGF2,IL2RG,ADOR
4 A2A,CD74
IGFBP2,SERPING1,CD4,ITGAL,IGF2,C4
1 B,IL2RG,CD74,CXCL13
2 IGFBP2,CD4,ITGAL,IGF2,IL2RG,CD74
3 IGFBP2,CD4,ITGAL,IGF2,IL2RG,CD74
4 IGFBP2,CD4,ITGAL,IGF2,IL2RG,CD74
1 DRD2,PENK,ADORA2A
LHX8,TRH,IGF2,DRD2,PENK,ADORA2
1 A,CD74,GPR88,CXCL13
SCN4B,IGFBP2,CD4,RT1A2,ITGAL,FCGR3A,TRPM6,IL2RG,DRD
1 2,RGS9,ADORA2A,CD74,RT1-DA
1 DRD2
1 DRD2
1 CD4,RT1-A2,CD74,RT1-DA
1 ITGAL,C4B,FCGR3A,RT1-DA
1 CD4,RT1-A2,CLDN2,ITGAL,RT1-DA
RT1-A2,FCGR3A,CD209B,OLR1,RT11 DA
1 IGFBP2,IGF2
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